cox proportional hazards models



patients
patients
clinical
exercise ; cardiovascular
patient ; hf
complications ; follow-up
reporting ; cell ; anand
doxorubicin ; injected
doctors ; blood transfusions
adverse events


dxa
heart failure
correlation
liver disease
adverse events
hf ; pna
exercise ; cardiovascular ; health
renal artery stenosis
retrospective cohort study
acute care surgery ; heart transplant
primary end point ; inhospital ; mortality


periodic breathing ; heart beat
observational cohort study
heart failure ; latin america
retrospective cohort
multivariate models
hf
mortality
patients


doctors


heart rate
heart failure
united states
heart failure
surgery



heart failure





witness ; anemia
exercise
patients
dodson
end point
chf
randomised
frailty
collateral growth
autonomic balance
lv fibrosis
hfpef

st2 ; functional capacity
heart failure ; mortality
cardiology ; hospital
follow-up duration
hf ; hf
patient ; hospital ; heart failure
inpatient ; medical ; conditions
frailty ; hf
correlated ; mixed linear models
extended criteria cardiac transplantation
secondary outcomes ; quality of life
heart rate variability ; risk stratification ; cardiac ; patients



patients
outcome
policy
compliance
prognostic
heart failure
chf
air ; heart failure
patients ; followed up
patients ; cardiovascular disease
hf ; mi
extracorporeal support
heart failure ; disease ; therapeutics
secondary outcomes ; hemostasis
retrospective matched cohort study
remote ischemic conditioning ; patients ; heart failure
heart failure ; patients ; bisphosphonates
acute right heart failure ; pulmonary hypertension
caspase-3 ; gene expression ; heart failure
diuretic ; heart failure ; outcomes
patients ; functional capacity ; symptoms
genes
end point
patients ; hypertension
american ; hf
heart rate ; arterial pressure
follow-up ; patients
chronic hf ; death
cardiac amyloidosis
training ; heart failure ; patients

etiology ; diagnosed
patients ; hfpef
ejection fraction ; bnp
antiarrhythmic ; medication ; death
patients ; therapy ; beta blockade
chf ; patients ; intubated
surgical ; hypothermic circulatory arrest
primary outcomes ; functional capacity ; quality of life
collected ; patients ; systolic dysfunction


frailty ; heart failure

patients
implanted
clinical
patient ; conditions
ea ; afterload
deaths ; strokes
ras ; atherosclerosis
exercise ; quality of life ; heart failure
micrornas ; heart failure ; disease
hazard ratios ; cox regression analysis
psss ; exercise ; training ; outcomes
heart failure with preserved ejection fraction
cardiology ; bromodomain ; halts ; heart failure
heart failure ; hospitalization ; cardiovascular death
mitral stenosis ; medical treatment ; heart failure
vasopressin ; congestive heart failure
cardiotoxicity ; patients ; breast cancer
medication ; sst2
physician ; hospital ; physician
mortality ; sts
pde2 ; hf
hospital ; coprimary outcome
heart failure ; public ; health
postoperative ; albumin
lvet ; aortic pressure
physician ; outcomes ; discharge
costs ; expenditures
heart failure ; hf ; therapy
cardiac ; symptoms ; congenital ; lesions
spironolactone ; systolic heart failure
molecular scaffolds ; heart ; pathology
functional ms ; reported ; patients ; degenerative mr
epidemiology ; chronic heart failure ; bisoprolol
heart failure ; hf ; leading ; mortality ; society
covariate adjustment ; cox proportional hazards models
tolvaptan ; vasopressin type 2 receptor antagonist
meta-analysis


patients
patients
patients
readmission
chf
readmission
stable hf
follow-up
quality of life
follow-up
outcomes ; patients ; heart failure ; emergency department
meta-analyzed ; mortality ; random-effects models
patients ; cardiac ; inflammatory ; biomarkers
decompensated hf ; cardiovascular ; hospitalization
hgb ; correlated ; baseline ; hrqol
preserved ejection fraction ; outcomes
therapeutic ; biomarkers ; chronic heart failure
seattle heart failure model
descriptive statistics ; cox proportional hazards models
patients ; acute kidney injury ; postoperatively
patient ; postoperatively ; multiorgan failure ; sepsis
psychometric ; self-care of heart failure index version 6.2
randomized ; walking ; patients ; severe heart failure
heart failure ; cox proportional hazard analyses
t1-mapping ; baseline ; heart failure
pharmacological ; acute heart failure
patient ; surgery ; echocardiography
hemodynamic phenotype ; fontan
coronary angiography ; lesions
dialysis ; patients ; implantation
sternal ; heartmate ii
vo2max ; significance
exercise ; life expectancy
multivariate analyses
elevated ; hf
patients ; esrd
outcome ; tug test
biomarkers
drug ; japan
prognostic
heart failure
healthcare
clinical
cardiac




heart failure with preserved left ventricular ejection fraction
hr variability ; cardiac death
correlations ; hospital ; longitudinal ; change
patients ; chronic kidney disease ; ckd
disease ; lead ; hypertension ; kidney failure
readmission ; hospital ; heart failure ; discharge
skeletal muscle ; exercise capacity ; fontan circulation
physician ; outcomes ; patients ; heart failure
prevalence ; systolic hf
outcome ; all-cause readmissions
prognosis ; pathophysiological
medication ; resting hemodynamics
correlation ; postsystolic function
patients ; lvad ; implantation
secondary outcome ; patient ; post
income ; expenditure ; health
aac ; cardiac hypertrophy
aha ; esc
paucity ; outcomes
clinician ; hf
end stage heart failure
diagnostic ; hf
patients ; heart failure
acute heart failure
systemic blood pressure
patient ; circulation
cpgs
north america
therapy
prospective
patients
surgery
endothelial function ; flow-mediated dilatation
nursing ; nursing
hf ; chromatin hyperacetylation
septal ; diagnostic ; filling pressures
telehealth ; longitudinal ; medicare
preoperative ; operative ; outcomes
public reporting ; patients ; hospitals
sinus rhythm ; adverse outcomes
patients ; heart failure ; cardiac rehabilitation
spironolactone ; severe heart failure
myocardial infarction
physicians ; patients ; hf
anemia ; patients ; heart disease
exercise ; training ; outcomes
rate-control ; outcomes
ingenuity pathway analysis
post-lvad ai
patients ; surgical
acute heart failure
cohort study
qrs duration
patients ; hospitals
adverse events
follow-up
mortality
deficit index
gls
surgery

prognostic ; anaerobic threshold ; heart failure
renin-angiotensin-aldosterone system inhibitors ; heart failure
chf ; unilateral renal dnx ; cardiac ; autonomic balance
mitral regurgitation ; hf ; symptoms ; surgery
compliance ; attrition
heart block ; pulmonary artery ; bivp
resistin ; inflammation ; metabolism ; heart disease
cad ; systolic hf ; prognostic
diuretic ; outcomes ; hf
follow-up ; cardiovascular events ; deaths
microarray ; genes ; heart failure
patients ; patients ; echocardiographic
surgical ; patients ; functional ms
congenital ; heart ; lesions
quality-of-life ; patients
pvf ; pb
economic ; accounting ; cost
nurses ; patients ; disease
sst2 ; therapy
hf ; surgical
icu ; mortality
cardiac function ; catheter
crt ; patients
beta-blockers
chf ; patients
rm
hf
ischemic cardiomyopathy ; mortality
unfolded protein response ; cardiac sodium ; systolic ; heart failure
diastolic dysfunction ; patients ; peripheral artery disease
western blot ; immunohistochemistry ; electron microscopy
angiotensin receptor neprilysin inhibitor ; heart failure
evidence ; idiopathic dilated cardiomyopathy
patient ; diagnosed ; hypertensive lv dysfunction
hypoalbuminemia ; prognostic ; patients ; heart failure
prognosis ; hf ; etiologies
surgery ; mva
exercise ; training ; endothelial function
prospectively ; ffm ; stable
coronary disease ; leading ; heart failure
end point ; neurological ; cardiovascular events
complications ; dialysis ; patients
signalling pathways ; cardiac remodelling
patients ; heart transplant ; ecct
clinical ; hfpef
dpp-4 inhibitors ; drugs
left bundle branch block
minnesota ; hf
frailty ; hf
proteome ; hdl
heart failure ; nurse
proteins ; tac
cardiac cachexia
rehospitalization
exercise ; exercise
heart rate
crf
dash
patients ; diabetes ; eo-cfus ; functional capacity
risk stratification ; death ; all-cause hospitalization ; heart failure ; clinic ; outpatients
cardiac-resynchronization therapy ; heart failure ; narrow qrs complex
hospital-to-home ; hospital ; readmission ; congestive heart failure
hfref ; hfpef ; patients ; regression line
physician ; death ; readmission ; discharge ; patients ; heart failure
nitroxyl ; hno ; acute ; heart failure
change ; lvet ; admission ; follow-up ; outcome
multivariate models ; odds ratios ; accounting ; hospital
6-minute walk distance ; peak vo2 ; baseline
pharmaceutically
healthy ; engage ; exercise
hospitals ; outcome
chf ; patients
patients ; transplants
peak vo2
hospitals
patients
patient
remodelling ; hf ; haemodynamic ; neuronal stressors
heart failure ; patients ; rheumatoid arthritis ; tnf antagonist
mortality ; hf ; hospital ; admissions ; transplant ; ventricular assist device
coronary artery disease ; cad ; systolic heart failure ; hf
preoperative ; hypoalbuminemia ; prognosis ; lvad ; surgery
grade ; holosystolic murmur ; third heart sound ; apex
psoriasis ; atherosclerosis ; cardiovascular events ; rotterdam study
death ; stroke ; hospitalisation ; heart failure
renal artery stenosis ; ras ; peripheral arterial disease
clinical ; connected ; elevated ; resistin ; heart failure
subclinical ; atherosclerosis ; linear models
wilcoxon matched-pairs signed-rank tests
incidence ; esrd ; outpatients ; hf
left ventricular assist device ; right ventricular support
baseline ; ecgs ; electrocardiographers
right ventricular function ; prognosis ; heart failure
deficit index ; biological phenotype ; mortality
exercise intolerance ; chronic heart failure ; prognosis
heart transplantation ; left ventricular assist device
ecct ; heart failure ; therapy ; patients
atrial fibrillation ; patients ; heart failure
cachexia ; right ventricle ; heart failure
avd ; vvd ; free wall rs
preoperative ; clinical ; mortality
unilateral renal denervation ; autonomic balance ; chronic heart failure
expression ; type i regulatory subunit ; ri ; hf
heart failure ; hf ; morbidity ; mortality
patients ; heart failure ; diagnostic ; medication ; follow-up
patient ; heart failure with reduced ejection fraction
cpet ; exercise rehabilitation ; patients ; chf
eplerenone ; primary composite endpoint
baseline ; outcomes ; ecct ; cardiac transplant
vegf inhibition ; cardiac function ; remodeling
heart failure ; hf ; cardiovascular ; hospitalization
heartmate ii ; lvads ; patients
patients ; extubated ; blood ; transfusion
patient ; asymptomatic ; follow-up
patients ; discharge ; follow-up ; medication
changing ; β-blocker ; sst2
bromodomain proteins
mirnas ; cardiac ; pathogenesis
prescribing ; medications ; heart failure
meta-analysis ; mortality ; patients
lesions ; septal ; surgical
quality of life ; mlhf questionnaire
coronary heart disease ; stroke ; heart failure
patient ; mortality ; therapeutic
btt ; dt ; implantation
heart failure ; readmission ; outcome
st2 ; patients ; plasma
follow-up ; hf
biomarkers ; hf
adverse event ; hypotension
outcomes ; hospitalization
patients ; condition ; economic
patients ; cad ; cad
renal dysfunction ; morbidity
patients ; lvad ; implantation
cardiac hypertrophy ; energy metabolism
meta-analyses ; patients
patients ; trastuzumab
patient ; clinical ; symptoms
renal dnx ; plasma
heart failure ; disease ; medical
dna ; genotyped
malondialdehyde
follow up ; hf
patients ; blood ; medication
anemia ; heart disease
patients ; randomized
hospital ; discharge
hospitals

change ; readmissions ; follow-up ; heart failure ; readmission
myxomas ; right atrium ; embolize ; pulmonary arterial vasculature
orthotopic heart transplantation ; oht ; end-stage heart failure
right atrial myxoma ; pulmonary embolism ; right heart failure
nfat ; mir-25 ; transcription factor ; hand2 ; heart failure
elevation ; resistin ; correlated ; ejection fraction
framingham heart study ; hf ; ef
exercise ; adverse events ; coronary artery disease ; cad
diuretics ; symptoms ; patients ; heart failure ; hf
patients ; clinical ; radiological ; hf ; hospitalization
east ; rhythm control therapy ; cardiovascular ; complications
cardiac overexpression ; mammalian enabled ; mena ; heart failure
lvas ; bridge to transplantation ; destination therapy
apoptosis ; chronic heart failure ; tachycardia
dysfunction ; pump ; driveline ; pump ; curative
cpcs ; functional capacity ; peak vo2
evidence-based ; therapies ; patients ; fes
nicorandil ; orally ; doxorubicin
st2 ; prognosis ; heart failure
clinical ; outcomes ; hfpef
ischemic ; inflammatory ; abdominal
evidence ; acp ; clinical practice guidelines
medline ; embase ; cinahl
intubations ; congestive heart failure
correlations ; acr ; cms
follow-up ; hf ; deaths
saxagliptin ; sitagliptin
frailty ; heart failure ; health
caspase ; myocardium
heart ; heart failure ; arrhythmias
evidence
patients ; implantation ; crt
world health organization ; hf
diagnosis ; therapy
degs ; osprey
clinical ; change
meta-analysis
medicare ; policy
qrs
chf
deficit index
mortality


β-blocker ; uptitration ; hfpef
gastrointestinal bleeding ; patients ; ventricular assist devices ; cardiac ; nurse
qt intervals ; sd of all qt intervals ; sdqt
bottleneck stent ; chronic myocardial ischemia ; heart failure
remote monitoring ; hospital ; discharge ; patients ; heart failure ; meta-analysis
prognostic ; right ventricular contractile reserve ; patients ; pulmonary hypertension
baseline ; echocardiograms ; evidence ; reverse remodeling
st2 ; ambulatory ; patients ; heart failure ; functional capacity ; outcomes
lv filling pressure ; stable ; severe systolic hf
titin hypophosphorylation ; myocardial dd
patients ; atrial fibrillation ; pacemaker
t1 mapping ; clinically ; myocardial fibrosis
diagnosis ; medical ; heart failure ; canadian cardiovascular society
psychosocial ; exercise ; training ; heart failure ; hf ; patients
cardiac catheterization ; patient ; extubated ; transferred
pump ; pump ; pump thrombosis ; hemolysis
attrition ; compliance ; exercise ; injections ; patients
hrqol ; exercise ; training ; baseline ; hgb
noc ; outcomes ; outcome ; admission ; discharge
cardiac resynchronization therapy ; patients ; heart failure
randomized ; double-blind ; active ; placebo
inpatient ; patients ; discharged ; hf
report ; aric ; hf
skeletal muscle ; correlated ; vo2 max
ees ; ventricular-arterial coupling
patients ; pneumonia ; surgical ; conditions
autonomic nervous system ; activity ; qtv
diastolic failure ; cardiomyopathic
patients ; therapy ; hospitalized ; cardiovascular
meta-analysis ; mortality ; patients
myocardial tissue ; pka
body mass index ; crf ; exercise
catheter ablation ; sinus rhythm
disease ; accounting ; cardiac transplants
ethics rounds
patients ; prognosis
exercise



renal dnx ; cardiac ; autonomic balance ; chf ; sympathetic tone
heart rate reduction ; ivabradine ; left ventricle ; heart failure ; patients
anemia ; patients ; heart disease ; clinical practice guideline ; american college of physicians
biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
incidence ; end-stage renal disease ; outpatients ; systolic heart failure
heart failure ; pathophysiology ; diagnosis ; medical treatment ; nursing
rvpo ; bivp ; correlated ; rs synchrony
parasympathetic neurotransmission ; acetylcholinesterase inhibition
echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
neurohormonal ; pathophysiology ; congestive heart failure ; chf
exercise ; training ; patients ; chronic heart failure ; high-density lipoprotein
cardiovascular death ; hf ; hospitalization ; exercise ; training ; patients ; btes
acute ; autonomic nervous system ; qtv ; hf ; patients
resistin ; acute ; anthracycline-induced cardiotoxicity
myocardial ; pde2 ; expression ; activity ; hf
clinical ; outcomes ; hospitalisations ; readmissions ; mortality
heart rate ; aortic ; blood flow ; doxorubicin
bat ; sympathetic outflow ; parasympathetic activity
congestive heart failure ; chf
chromatin subproteome ; diseased ; heart
left pulmonary artery ; right pulmonary artery
resistin ; breast cancer ; patients ; cardiotoxicity
cpcs ; outcomes ; patients ; diabetes
dash ; mortality ; heart failure ; health
differential effect ; lvef ; mortality
dobutamine ; furosemide ; outcome
mirnas ; therapeutic ; heart failure
witness ; sickle cell disease ; anemia
mri scanner ; baseline ; heart failure
health buddy program ; hospital ; hospitalized
clinical ; therapeutic
rad variant ; congestive heart failure
physician ; conditions ; hospital ; discharge
cardiac stress ; β-ar ; drive
psss ; btes ; exercise
therapeutic ; patients ; heart failure
frailty ; health ; outcomes
syndrome ; heart failure ; fontan
health buddy program ; telehealth
bisoprolol ; mortality
chf ; intubation
medicare ; hospitalizations
student t test ; confidence intervals ; cis ; regression analyses
myocardial diastolic dysfunction ; dd ; collagen deposition ; titin
systolic ; diastolic mitral leaflet motions ; organic ; lesion
stress doppler echocardiography ; prognostic ; pulmonary hypertension ; patients
circulating progenitor cells ; outcome ; heart failure ; patients ; longitudinal
lv strain ; strain ; echocardiography ; baseline ; ablation
correlated ; septal ; wall ; avd ; free wall cs ; vvd
etiologic ; acute rv failure ; left ventricular dysfunction
biventricular pacing ; left heart twist ; strain ; right heart failure
followed up ; adverse events ; death ; transplantation ; circulatory assist device
morbidity ; mortality ; quality of life ; patients ; hf
cpcs ; functional capacity ; outcomes ; heart failure ; hf
ctnt ; nt-probnp ; hf
protein kinase a ; guanylate cyclase ; contractile response
hr reduction ; beta blockers ; exercise capacity ; hfref
primary outcome ; sympathetic activity ; myocardial washout
proof-of-principle cohort study ; canada
cardiopulmonary ; exercise ; prognostically ; heart failure
inhospital ; mortality ; patients ; bnp ; mortality
clinical ; radiological ; hf ; quality of life
outcomes ; costs ; patients ; heart failure ; hf
right ventricle ; rv ; cardiac function ; medical
mortality ; deaths ; acs ; consultation ; operation
rv dysfunction ; correlated ; lean body mass
transcatheter ; invasive ; surgery
beta blockers ; mortality ; patients ; heart failure
pd ; congestive heart failure ; chf
hf ; valve plasty ; mva
pressure ulcers ; surgical ; patients
baseline ; st2 ; interquartile range
outcome ; death ; hospitalization ; heart failure
therapeutic ; diagnostic ; fluid overload
outcome ; change ; hospitalized ; heart failure
follow-up ; outcomes ; mortality
regression models ; comorbidities
resistin ; heart failure ; breast cancer
exercise ; clinical ; outcomes
symptoms ; patients ; nyha
chelation ; heart iron
patients ; consultation ; abdominal
patients ; chronic organ failure
diagnostic ; complication
follow-up
mortality

ejection fraction ; clinical ; cardiac resynchronization therapy ; mild heart failure
surgical ; aortic valve insufficiency ; left ventricular assist device ; implantation
left ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
apoptosis ; pacing-induced dilated cardiomyopathy
right atrium ; prolapse ; tricuspid valve ; stenotic physiology
california office of statewide health planning and development patient discharge data nonpublic file
cardiac catheterization ; thrombotic obstruction ; right coronary artery
clinical ; echocardiographic ; invasive ; hemodynamic ; outcome
hfpef ; sodium ; ventricular ; vascular stiffness
primary outcome ; functional capacity ; 6-minute walk test ; 6mwt
chronic heart failure ; chf ; sympathetic tone ; autonomic imbalance
chf ; atrial explants ; cells ; explants
fully magnetically levitated left ventricular assist system ; hf
fontan failure ; systolic ventricular function ; liver disease
heart failure ; leading ; mortality ; western ; society ; cardiovascular diseases
nursing ; outcomes ; hospitalized ; hf
extracorporeal membrane oxygenation ; refractory right heart failure
protein ; genes ; western blot ; dna fragmentation ; tunel
elevated ; cardiac filling pressures ; adverse outcomes
patient ; implantable cardioverter-defibrillator
medicine ; dilated cardiomyopathy ; patients ; heart failure
patients ; trastuzumab ; cardiac ; comorbidities
electromechanical delay ; dyssynchronous heart failure
cardiac ; mena deletion ; cardiac dysfunction ; hypertrophy
economic ; patients ; heart failure ; québec ; canada
phenotype ; perioperative ; deaths
left bundle-branch block ; lbbb
bets ; tac ; hf
patients ; systolic function ; therapeutic
correlation ; flow-mediated dilatation
prospective studies ; cpg ; hf
cox regression ; cardiovascular events ; psoriasis
heart failure ; protein kinase a ; expression
nt-probnp ; sensitivity
randomized ; dopamine ; nesiritide
quality of life ; seattle heart failure model
follow-up ; patients ; hf
patients ; ahf ; risk stratification
clinical ; nitrite ; vascular
neurological ; cardiovascular ; bound
patients ; madit-crt
consultations ; patients ; patients
transfusion ; mortality
czech republic
cardiac ; nurses
patients ; randomization
c statistics
heart failure
health
preoperative ; serum albumin ; patients ; left ventricular assist device ; implantation
western blots ; monoclonal antibodies ; ser83 ; phosphorylation ; hf
hrqol ; linear mixed models ; intention-to-treat
interleukin receptor ; st2 ; beta-blocker ; therapy ; chronic heart failure
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
patients ; clinical ; echocardiography ; baseline ; shunt ; implantation
exercise intolerance ; heart failure ; exercise ; diagnosis ; prognosis ; therapeutic
functional ms ; ring annuloplasty ; ischemic mr ; lv dilatation
new york heart association classification ; 6-min walk test ; quality-of-life
pathophysiology ; hf ; diagnosis ; medical ; nursing
vasopressin receptor antagonist ; tolvaptan ; heart failure ; patients
change ; paco2 ; cerebral ; blood flow ; perfusion ; carotid
correlations ; cox models ; st2 ; functional capacity ; outcomes
patients ; physicians ; hospitals ; new jersey ; new york
all-cause hospitalisations ; sts
psoriasis ; patients ; diastolic blood pressure ; body mass index
patients ; ecmo ; patients ; vad ; ecmo ; vad
inotropic effect ; beta blockers ; heart failure
anticoagulation ; therapy ; heart disease ; rate control
mortality ; morbidity ; health-care ; budget
energy metabolism ; heart failure ; hypertrophied ; heart
nt-probnp ; circulation ; hf ; patients
hr reduction ; ivabradine ; tac ; ea
patients ; pad ; ankle-brachial index
functional ms ; lv dilatation ; functional ms
baseline ; mechanical cardiac support ; renal function
renal dysfunction ; mechanical cardiac support
implanted ; patients ; adverse events ; follow-up
patients ; left ventricular dilatation ; dysfunction
grade ; evidence ; anemia ; patients ; heart disease
follow-up ; lvad ; patients ; heart failure
baseline ; rhythm-control ; rate-control
patients ; heart failure ; systolic heart failure
hf ; epidemiology ; health ; hf
functional ms ; medical treatment ; surgical
hemoglobin ; health ; outcomes
ventricular assist devices ; therapies
heart failure ; hf ; chronic ; disease
outcomes ; heart failure ; hf
correlates ; coagulability
exploratory factor analysis ; cfa
pb ; patients ; hf
clinic ; clinicians ; patients
readmissions ; hospital
icd ; patients
patients ; patients
hf
inverse correlation ; pro-adrenomedullin ; mr-proadm ; ffm
cardiorespiratory fitness ; body mass index ; heart failure ; mortality ; cooper center longitudinal study
bnp ; nt-probnp ; diagnostic ; prognostic ; biomarkers ; patients ; heart failure
exercise
receptors ; adenylyl cyclase ; g-protein coupling
patients ; heart failure ; hf ; preserved left ventricular ejection fraction ; hfpef
n-terminal pro-b-type natriuretic peptides ; plasma ; heart failure ; patients
ejection fraction ; ef ; infarct ; collateral growth ; myocardial perfusion
heart failure ; hf ; elevated ; sympathetic activity ; parasympathetic control ; heart
atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
physical ; activity ; cardiovascular ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
atp ; xo-mediated ros ; mitochondrial respiration ; contractile function
mortality ; patients ; implantable cardiac defibrillator ; meta-analysis
patients ; end-stage heart failure ; implantation ; ventricular assist device
patients ; systolic hf ; etiology ; coronary angiography
hf ; symptom ; cardiac murmurs ; blood pressure
exercise intolerance ; symptom ; chronic hfpef ; quality of life ; qol
isoproterenol ; cxl-1020 ; myocytes ; hearts
pyridostigmine ; myocyte ; collagen ; left ventricle
repolarization ; patients ; heart failure ; ventricular tachycardia
cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
biventricular dysfunction ; outcome ; patients ; heartmate ii
patients ; hf ; spontaneous vt ; qt intervals
nursing ; mandate ; accountable ; outcomes ; nursing
signaling pathways ; pressure-overload-induced heart failure
tug test ; patients ; copd ; chf ; crf
clinical ; patient ; hemodynamically ; cpr
ecmo ; egfr ; egfr
sonographic ; histological ; gastrointestinal
complications ; acs ; patients ; patients ; vad
tnf antagonists ; nbdmard
rotterdam study ; psoriasis ; cardiovascular ; outcomes
evidence ; schfi v.6.2 ; clinical
energy substrate metabolism ; hearts ; aac
cvd ; psoriasis ; hazard ratio ; confidence interval
diabetes mellitus ; cardiovascular disease ; baseline
rule ; patients ; cad ; patients ; cad
hospital ; cardiac ; hospital ; south dakota
exercise ; haemodynamic ; pulmonary
medical
diagnostic ; rule ; prospectively
cachexia ; rv function
mortality ; readmission
hospital ; rehospitalization
hospital ; mortality
acute hf
administration ; chf
prospective
hospitals
clinical
cardiac death
mechanical cardiac support ; renal function ; end-stage heart failure
reported ; functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
follow-up ; deaths ; heart transplantations ; lv assist device implantations ; heart failure ; admissions
global left ventricular longitudinal systolic strain ; cardiovascular events ; patients ; atrial fibrillation
hf ; transition ; compensated lv hypertrophy ; hf ; hhd
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
natriuretic peptide ; biomarkers ; point of care ; poc
sympathetic ; parasympathetic activity ; hf ; symptoms ; disease
prevalence ; bnp ; patients ; pad ; bnp ; hf
spironolactone ; hyperkalemia ; acute kidney injury
chronic myocardial ischemia ; heart failure ; therapeutic
patients ; systolic blood pressure ; renal impairment ; hypertension
patients ; hfpef ; adverse outcomes
outcomes ; exercise ; training ; patients ; ambulatory ; hf
evidence ; parasympathetic ; therapeutic ; hf
heart failure ; hf ; condition ; morbidity ; mortality
jugular venous pressure ; peripheral oedema ; patient
medical treatment ; hf ; hf ; symptom ; mva
baseline ; hgb ; exercise ; training ; kccq
surgical ; revascularization ; revascularization
redo sternotomy ; cardiopulmonary bypass
clinical ; rule ; cad ; systolic hf
morpholino-based ; nucleolin ; protein expression
medical treatment ; hf ; functional ms ; medical treatment
cardiovascular ; conditions ; patients ; hf
cytoscape ; functional enrichment analysis ; david
hypertension ; diabetes ; ischemic ; etiology
nt-probnp ; patients ; acute heart failure
health ; health ; u.s. ; drug ; administration
patients ; lvad ; patients ; biventricular support
patients ; fontan circulation ; svr ; cardiac index
fontan circulation ; skeletal muscle ; metabolic
hereditary ; congenital ; heart ; death
mineralocorticoid receptor antagonists
albumin ; lvad ; postoperative
patients ; heartmate ii ; lvad
evidence-based ; patient ; outcomes
bisphosphonate ; heart failure
right heart circulation ; right heart failure
signalling pathway ; remodelling
mi ; mi ; hf
remodeling ; emd
costs ; outcomes
secondary outcomes
clinical
patient
diagnosis ; heart failure with preserved ejection fraction ; clinical ; doppler echocardiography
xanthine oxidase inhibition ; left ventricular ; systolic ; diastolic function ; cardiac volume overload
spironolactone ; diagnosed ; systolic heart failure ; clinical
selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; patients ; heart failure
outcomes ; myocardial ischemic events ; patients ; cardiac resynchronization therapy
β-blockade ; cardiac angiogenesis ; heart failure ; vegf signaling pathway
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
hf with preserved ejection fraction ; hfpef ; hypertension
patients ; heart failure ; hf ; heart failure adherence and retention trial ; hart
clinical ; symptoms ; hfpef ; symptoms ; breathlessness ; fluid retention
myocardial infarction ; left anterior descending coronary artery occlusion
end points ; nyha functional class ; quality-of-life ; 6-minute hall walk
report ; patients ; aortic valve ; surgery ; post-lvad ai
immunodetection ; nt-probnp ; antibodies ; terminal
heart ; hr reduction ; patients ; systolic heart failure
walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; heart failure
oxidative stress ; gtpase ; rac1 ; activity ; hearts
medications ; outpatients ; heart failure ; ncdr pinnacle
end point ; cardiovascular death ; cardiac transplant ; secondary end point ; death
resistin ; insulin resistance ; monocytes ; inflammatory
heart failure ; hf ; latin america ; health ; hf
heart failure ; clinical ; medicine ; prevalence ; coronary disease
palliative care ; patients ; terminal ; disease ; therapeutic
death ; hf ; hospitalization ; crt ; hazard ratio
rehospitalization ; medicare ; discharged ; nursing
diagnostic ; hfpef ; medical history ; physical examination


elevated
readmission ; patients
psoriasis ; systemic ; followed up
degs ; ischemic heart failure
conditions ; remodelling ; leading ; heart failure
heart failure ; emergency department ; patient ; outcomes
intravenous ; symptoms ; patients ; heart failure
rv dysfunction ; prognosis ; hf
pd ; clinical ; hospitalizations ; complications ; therapy ; end-stage hf
diagnosis ; clinical ; prognostic ; diastolic dysfunction ; leading ; hfpef
chromatin-associated proteins ; chromatin structure ; changing ; dna ; gene expression profile
nt-probnp ; hf ; patient ; plasma ; immunoprecipitation ; mass spectrometric analysis
right ventricle ; leads ; stroke volume ; shortens ; left ventricular ejection time ; lvet
β-adrenergic receptor blockade ; mortality ; all-cause hospitalizations ; patients ; heart failure ; hf
patients ; diagnosis ; congestive heart failure
mitochondrial structure ; sarcomeric microstructure
chf ; patients ; emergency department ; intubated
mortality ; lcx ; lad ; disease
ppr ; acr ; cms ; correlated
gut ; inflammation ; heart failure ; patients ; heart failure
patients ; heart failure and reduced ejection fraction
gait ; therapy ; lokomat ; heart failure ; patients
patient ; implantable cardioverter-defibrillator
noninvasive ; patients ; pulmonary hypertension ; heart failure
lvet ; sensitivity ; specificity ; death ; icu
patient ; symptomatic ; therapeutic ; exercise ; hemodynamic
cardiac failure ; death ; patients ; type 2 diabetes ; diabetes ; heart failure
healthy ; hdl ; chf-nyha-iiib ; hdl
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
prognosis ; patients ; chf ; therapeutic ; neurohormonal systems
patients ; uptitration ; heart rate ; renal function ; spironolactone
evidence ; micrornas ; mirnas ; pathogenesis ; heart failure
beta-blocker ; patients ; resting hr ; bpm ; p value
qt variability ; qtv ; repolarization ; qtv ; cardiac death
new zealand ; renal dnx ; pacing-induced chf
ambulatory ; hf ; patients ; left ventricular ejection fraction
paradigm-hf ; shift ; chronic heart failure ; chronic heart failure ; cardiology
physician ; follow-up ; discharge ; death ; readmission ; patients ; heart failure
dialysis ; patients ; adverse events ; echocardiographic ; outcomes
obese ; zsf1 ; heart failure with preserved ejection fraction
transoesophageal echocardiography ; shunts ; thrombosis
hand2 ; healthy ; heart muscle ; cells ; phenotype ; pathological ; hypertrophy
cross-talk ; heart ; adipose tissue ; cachectic heart failure ; patients ; prospective study
arterial tonometry ; lvet ; prognostic ; patients ; precapillary ph ; heart failure
heart magnetic resonance imaging ; chelation ; compliance ; heart disease ; patients ; thalassaemia major
t1-mapping ; mri ; tidal respiration ; myocardial t1 ; heart failure
advantage ; poc
costs ; clinical
cardiovascular disease ; baseline
rhythm control therapy
proteins ; subproteome
all-cause readmissions
hospital compare ; ami ; mortality
psoriasis ; cardiovascular disease ; cvd
septal ; likelihood ratio
systems proteomics ; cardiac chromatin ; nucleolin ; cellular plasticity ; cardiomyocytes
cardiac dysfunction ; subcellular ; metoprolol ; heart failure ; myocardial infarction
hemoglobin ; exercise ; training ; health ; patients ; chronic heart failure ; hf-action ; randomized
ras-blocker ; uptitration ; clinical ; outcome ; patients ; hfref ; hfpef
myocardial collagen ; collagen cross-linking ; titin ; isoforms ; phosphorylation
cardiac magnetic resonance postcontrast t1 time ; outcome ; patients ; heart failure ; preserved ejection fraction
lv diastolic dysfunction ; filling pressures ; non-invasively ; doppler echocardiography
patients ; cardiovascular disease ; drs
therapy ; patients ; follow-up
diagnosis ; medical ; hf
mirnas ; cardiac remodeling ; heart failure
frailty ; heart failure ; hf
heart failure ; patients ; bisphosphonates
patients ; beta-blocker ; therapy
cardiomyocytes ; hypertrophic
physician ; patient ; admission ; admission
plasma ; collected ; hf ; patients
alendronate ; alendronate ; heart failure
transduction pathways ; engage ; signalling proteins
baseline ; patients ; resting hr ; bpm
gdmt ; gdmt ; bat
reported ; heart failure ; clcnka ; snp
clinical ; diastolic dysfunction ; mortality
acs ; patients ; oht ; transplant ; vad
patients ; β-blocker ; patients ; uptitration
regulation ; anti-inflammatory ; chf
principal ; hospital ; hf ; patients ; cms ; conditions
expression ; bax ; bcl-2 ; proteins ; pacing
hf ; patients ; rheumatoid arthritis ; ra
cardiac angiogenesis ; therapy ; cardiac function ; remodeling
symptomatic adult fontan ; saf ; patients ; catheterization
natriuretic peptides ; point of care ; ambulatory
alphalisa ; immunoassays ; nt-probnp
cardiotoxicity ; doxorubicin ; anti-neoplastic agent
patients ; heart failure ; left ventricular ; ejection fraction
reported ; patient ; implantable cardioverter-defibrillator
patients ; sinus rhythm ; antiplatelet agents ; anticoagulants
death ; c-statistics ; biological phenotype ; deficit index
drugs ; hf with reduced ejection fraction ; hfref
lv diastolic dysfunction ; combination ; figure ; hfpef
ambulatory ; icd ; patients ; mortality ; multivariable regression
fes ; patients ; preserved ejection fraction ; hfpef
myxomas ; cardiac ; benign tumors ; left atrium ; right atrium
nicorandil ; cytotoxic ; doxorubicin ; ehrlich carcinoma
gastrointestinal bleeding ; reported ; patients ; ventricular assist devices
arni inhibitors ; angiotensin-receptor neprilysin inhibitors
renal denervation ; dnx ; chf ; patients ; symptomatic
physician ; follow-up ; discharge ; physician ; outcomes ; patients ; heart failure
hyperkalemia ; acute kidney injury ; spironolactone ; clinical
heart failure with preserved ejection fraction ; hfpef ; cardiovascular reserve
patients ; heart failure ; elevated ; left atrial pressure ; symptoms ; hospital ; admission
mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ; hf
hospitalizations ; refractory congestive heart failure ; peritoneal dialysis
incidence ; vad ; acs ; consultations ; operations ; mortality ; morbidity
diagnostic ; bnp ; nt-probnp ; patients ; coronary artery disease ; cad

symptoms
clinical ; ecct
nt-probnp
nosignificant ; exercise
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
heart ; hospitalization ; death ; patients ; preserved left ventricular ejection fraction
kansas city cardiomyopathy questionnaire ; patients ; heart failure ; reduced ejection fraction
prevalence ; heart failure with preserved ejection fraction ; hfpef ; prognosis
zsf1 ; hypertensive ; obese ; zsf1 ; hypertensive ; diabetic
tissue doppler ; left ventricular filling pressure ; patients ; stable ; severe systolic heart failure
heart failure with preserved ejection fraction ; hfpef ; cardiovascular morbidity ; mortality
myocardial ; pde2 ; intracellular ; antiadrenergic ; therapeutic ; hf
shortened ; lvet ; icu ; admission ; prognostic ; patients ; precapillary ph ; heart failure
myocardial ; irs1 ; irs2 ; heart failure ; p38alpha ; mapk ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin ii ; infusion ; nephrectomy ; salt loading
transfusions ; patients ; heart disease
pvf ; pb ; bp
patients ; sst2 ; cardiovascular event
ecg ; crt ; clinical
remote monitoring ; rm ; heart failure
rv dysfunction ; cardiac cachexia
prevalence ; chronic heart failure ; hungary
follow-up ; hf ; hospitalization
combination ; exercise ; peak vo2 ; joint
spironolactone ; clinical ; medications
carotid intima-media thickness ; psoriasis
coronary occlusion ; collateral growth ; stent
patients ; narrow qrs complex ; crt ; patients
pharmacologic ; clinical ; pharmacologic
heart failure ; hf ; death ; crt-d
breast cancer ; patients ; chf ; reported ; clinical
pde2 ; hearts ; acute ; β-ar
clinicians ; patient ; anemic ; patients ; heart disease
point-of-care ; outpatient ; acute heart failure
eo-cfus ; mortality ; hazard ratio ; confidence interval
trastuzumab ; chf ; nontrastuzumab users
egfr ; diuretics ; hypertension ; patients ; esrd
incidence ; prevalence ; heart failure ; leading ; death ; hospitalisation
acute heart failure ; ahf ; symptoms ; heart failure ; hf
psoriasis ; patients ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
hf ; remodeling ; emd ; dyssynchronous failing heart
uptitration ; patients ; hr reduction ; beta-blocker ; therapy
genetic ; congestive heart failure ; haematopoietic cell transplantation
surgery ; medical treatment ; hf ; hypertension ; vasodilators ; diuretics
clinical ; clinical ; outcomes ; aldosterone antagonist ; heart failure
angiogenesis ; post-myocardial infarction ; heart ; heart failure
heart failure ; preserved ejection fraction ; myocardial infarction
prospective ; lvas
hdl ; chf ; vascular
hf ; hf ; mortality
physician ; hf ; cpgs
patients ; hfpef ; prospective
exercise ; health ; cardiac disease ; heart failure
hf ; hospitalization ; cardiovascular mortality
clinical ; coronary artery disease ; patients ; systolic heart failure ; etiology
ea ; total arterial compliance ; tac ; end-systolic elastance ; ees ; baseline
renal dysfunction ; all-cause mortality ; cardiovascular events ; postoperative ; cabg
baseline ; isoprenaline ; infusion ; sdqt ; hf ; patients
cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; hfpef
renal dysfunction ; mortality ; myocardial infarction ; coronary artery bypass grafting ; cabg
biventricular support ; heartmate ii ; lvad ; centrimag ; rvad ; mortality ; hospital ; discharge
pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
shunt ; implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
dopamine ; nesiritide ; placebo
clinician ; nonprescribing ; patient
biomedical ; nonprescribing ; patients
warrant ; erc ; epicatechin ; muscle
telehealth ; health ; outcomes ; medicare
baseline ; ea ; tac ; ees ; patients
patients ; severe hf ; prognostic ; hf
patients ; chf ; international classification of diseases
medline ; embase ; cochrane ; clinical
egfr ; vad ; ecmo ; vad ; ecmo
prognosis ; idiopathic dilated cardiomyopathy
tests ; cardiac growth ; disease ; chromatin ; remodeling
gait ; therapy ; lokomat ; heart failure ; patients
baseline ; crf ; hf ; mortality ; hf
rv dysfunction ; body mass index ; fat mass ; cachexia
myocardium ; expression ; pka ; downstream signaling
s3991 ; n2bus ; s12884 ; pevk
proteomics ; chromatin-associated proteins ; disease
cxl-1020 ; hno ; cxl-1051 ; t1
arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
pharmacologic ; acute hf ; adverse event ; chronic hf
nicorandil ; mitochondrial dysfunction ; heart failure ; cardioprotection
heartmate ; left ventricular assist system ; lvas ; patients ; heart failure
collect ; heart failure ; patients ; implantable cardioverter-defibrillator
self-care of heart failure index version 6.2 ; schfi v.6.2 ; psychometric
therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
heart failure ; cardiology-cardiovascular surgery consensus report ; heart failure ; disease
patient ; st-segment-elevation mis ; killip class ; comorbid ; conditions
end stage heart failure ; heart failure ; public ; health ; patient ; europe ; north america
patients ; heartmate ii ; biventricular support ; heartmate ii ; implantation
patient ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
tnf antagonists ; hf ; hospital ; admissions ; nbdmards ; ra
physician ; evidence
nurses ; magnet
mortality ; hospitals
randomized ; exercise ; exercise
multivariate analysis ; gls
patients ; ejection fraction
epidemiology ; myocardial infarction ; mi ; outcomes ; heart failure ; hf
heart rate reduction ; exercise ; heart failure with reduced ejection fraction ; beta-blocker
isoelectric focusing ; riα ; ser77 ; ser83 ; in vivo ; phosphorylation
correlated ; baseline ; nt-probnp ; mr-proanp ; mr-proadm
madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
prognostic ; admission ; brain natriuretic peptide ; bnp ; creatinine ; natremia
patients ; ras ; asymptomatic ; clinically ; hypertension ; nephropathy ; congestive heart failure
sdqt ; sd of rr intervals ; sdrr ; qtv ; heart rate variability
diagnostic ; tests ; cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments ; baseline
diagnosed ; patients ; hf ; drug treatment ; paf ; biosynthetic enzymes ; lyso-paf-at
patients ; t1 times ; cardiac events
sst2 ; sst2 ; outcomes
incidence ; hf ; ami ; mortality
lv ejection fraction ; pcwp
nucleolin ; genomic reprogramming ; disease
physician ; mortality ; hf ; physicians
chf ; chf ; patients ; intubated
logistic regression ; primary outcome ; secondary outcome ; death
egfr ; vad ; ecmo ; vad ; renal function
aucs ; septal ; qrs ; resynchronization
health care ; clinically ; gastrointestinal bleeding
hospital ; readmission ; patients ; heart failure ; follow-up
prospective ; diuretics ; morbidity ; mortality
readmission ; hospital ; congestive heart failure ; united states
ivc occlusion ; correlated ; rs ; rs synchrony
emergency department ; acute heart failure ; clinical ; patient ; collins
heart failure ; hf ; risk stratification ; inpatient ; outpatient
carvedilol ; metoprolol ; therapy ; heart failure ; patients
bet ; bromodomain-containing protein 4 ; brd4 ; cardiac
costs ; québec health insurance board ; costs ; ontario case costing initiative
report ; mitral valve plasty ; degenerative mitral regurgitation
evidence ; intravenous ; exercise tolerance ; quality of life ; patients ; heart failure
erythropoiesis-stimulating agents ; patients ; anemia ; heart disease
physicians ; public ; health ; air ; cardiovascular ; health ; lead ; hospitalisation ; death
evidence ; biomarkers ; pathophysiology ; chronic hf ; therapeutic
cardiopulmonary exercise test ; quality of life ; muscular ; peak quadriceps force
hf ; heart failure ; t2d ; type 2 diabetes ; skm ; skeletal muscle
morbidity ; mortality ; hfpef ; patients ; hf ; reduced ef
hf ; pyridostigmine ; basal heart rate ; sympathetic control of heart rate
patients ; idiopathic dilated cardiomyopathy ; tuscany ; evidence-based
ecg ; congenital ; accessory ; ion channelopathies ; cardiomyopathy
ras ; neprilysin inhibition ; change ; stable ; chronic heart failure ; systolic dysfunction
randomized ; af ablation
ejection fraction ; patients
echocardiographic ; crt
evidence ; economic ; lvad ; outcomes
end-stage heart failure ; mechanical cardiac support
change ; readmission ; follow-up ; follow-up
t1-mapping ; tidal respiration ; administration ; gadolinium-chelate contrast agent
medicare ; inpatient ; hf ; admissions ; acute ; hospitals ; united states
hf with preserved ejection fraction ; pef ; uptitration ; hospitalization
hf ; hhd ; salt loading ; uninephrectomy ; ang ii infusion
report ; dapc ; dystrophin-associated protein complex ; sarcomeric microstructure ; baseline
dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; rose ; acute heart failure ; randomized
outcomes ; catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction
myocardial ; titin hypophosphorylation ; heart failure with preserved ejection fraction ; metabolic
cardiac ; insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
if-channel inhibition ; hemodynamic ; exercise tolerance ; heart failure with preserved ejection fraction ; randomized
rv failure ; diagnostic ; left ventricular dysfunction
chronic heart failure ; yield ; atrial ; cells
mortality ; inpatient ; admissions ; hospital ; emergency department
hf ; mi ; reduced ejection fraction ; ef
mixed-methods study ; exercise ; patients ; heart failure
patients ; heartmate ii ; lvad ; centrimag ; rvad
patients ; hfpef ; kccq ; health ; prognostic
patients ; baseline ; serum creatinine ; serum potassium
pd ; diuretic ; peripheral edema ; functional class
echocardiographic ; cardiac resynchronization therapy ; crt
nt-probnp ; antibodies ; nonterminal epitopes
university of connecticut heart failure center ; heart failure ; nurse practitioner
anemia ; patients ; chronic heart failure ; hf ; prevalence ; outcomes
cardiac mrna ; inflammatory ; cell adhesion genes ; retn
chromatin subproteomes ; heart failure ; proteins ; chromatin structure
nbdmard ; tnf antagonist ; baseline ; covariates
hfref ; exercise ; resting hr ; bpm ; beta-blocker ; therapy
xo inhibition ; cardiomyocyte bioenergetics ; lv function ; chronic acf
patients ; heart failure ; heart failure ; nurses ; follow-up ; cardiology ; mortality
patients ; heart failure ; hf ; cardiopulmonary exercise test ; anaerobic threshold
preoperative ; renal dysfunction ; stroke ; myocardial infarction ; heart failure ; cabg
cox hazard models ; esrd ; death ; composite end point ; esrd ; death ; esrd
randomised-controlled trials ; rcts ; observational cohort studies ; contemporaneous control group
pyridostigmine ; administration ; methylatropine ; propranolol ; cardiac ; sympathovagal balance
baseline ; follow-up ; paf ; activity ; metabolic ; enzymes ; patients ; heart failure ; healthy
trastuzumab ; adjuvant ; outcomes ; cardiotoxicity ; congestive heart failure ; chf
carvedilol ; thromboembolic events ; patients ; heart failure ; β2-receptor haplotype
phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory
myosin ; protein-c ; phosphorylation ; troponin i ; phosphorylation ; hf
upr ; protein kinase r-like er kinase ; perk ; calreticulin ; chop ; hf
hf ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
patients
patients
chf ; proteins
costs ; physicians ; hospital
doxorubicin ; resistin
inferior vena cava ; ivc
surgery ; rheumatic ; surgery ; mva
chf ; patients ; hct ; city of hope
cardiac deaths ; atherosclerotic cad
peak oxygen consumption ; pulse ; patients
patients ; hf ; crt ; implantation ; complications
rv ; pathophysiologic ; rv dysfunction
infarcted ; left ventricle end-diastolic pressure
health ; followed up ; hf ; hospitalization ; death ; contact
economic ; nhs ; chronic ; disease ; exercise ; acute ; hospital
aldosterone receptor antagonists ; randomized ; morbidity ; mortality ; symptomatic systolic heart failure
deaths ; stroke ; hospitalisations ; heart failure ; follow-up
therapeutic ; biomarkers ; molecular dysfunction ; chronic hf
air ; cardiovascular ; health ; acute myocardial infarction
patients ; vad ; patients ; ecmo ; vad ; patients ; ecmo
genes ; ischemic heart failure ; biomarkers ; heart failure
outcome ; gls ; beat ; cox proportional hazards analyses
st2 ; c statistic ; net reclassification improvement ; integrated discrimination improvement
east ; rhythm control therapy ; diagnosis ; cardiovascular ; complications
hearts ; mena ; cardiac injury ; mena ; hf ; pathophysiology
scn5a ; upr ; downregulation ; cardiac ; genes ; hf
lipolysis ; expenditure ; b natriuretic peptides ; nps
cox proportional hazards models ; health ; health ; hazard ratios ; confidence intervals
tapse ; pasp ; downward ; regression line ; shift ; pasp ; tapse
right ventricular ; rv ; left ventricular assist device ; lvad ; outcomes
albumin ; inflammation ; hepatic ; prognosis ; patients ; lvad ; implantation
kccq ; kaplan-meier curves ; death ; all-cause hospitalization
olmsted county ; minnesota ; mi ; diagnosed ; hf ; followed-up
collected ; clinical ; death ; medical ; hospitalization ; hf ; clinic ; outpatients
prospective ; patients ; rule ; sensitivity ; specificity ; cad ; sensitivity ; cad
vascular endothelial growth factor ; vegf ; transition ; compensatory hypertrophy ; cardiac failure
left ventricular ejection fraction ; mortality ; patients ; heart failure ; heart failure survey ; israel
uptitration ; neurohumoral blockers ; hf ; hospitalization ; patients ; co-morbidity
incidence ; adjusted odds ratio ; hazard ratio ; death ; hf ; ami ; admission ; discharge
testosterone therapy ; exercise rehabilitation ; patients ; chronic heart failure ; testosterone ; double-blind ; randomized
health buddy program ; admissions ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
patients ; ras ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
patients ; ic ; multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy
nicorandil ; cardioprotection ; apoptotic signaling pathway ; dna fragmentation ; mitochondrial
proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
hospitalized ; ami ; complications ; heart failure ; kidney infection ; uti ; complications ; rehospitalization
pathophysiologic ; renal underperfusion ; renin- angiotensin-aldosterone pathway
hypoalbuminemia ; postoperative ; mortality ; patients ; left ventricular assist device ; lvad ; implantation
hr variability ; risk stratification
crt-d ; therapy
patients ; terminal ; diagnostic ; follow-up
hf ; ami ; hazard ratio ; mortality
apoptosis ; pathogenesis ; heart failure
bets ; transcriptional pause release ; pathological
evidence ; lvad ; transplantation ; patients ; budget
patients ; preserved lvef ; lvef
upr ; mrna splice ; cardiac ; hf
diuretic ; neurohormonal ; symptoms ; fluid overload
ecg ; atherosclerotic cad ; cardiac death
obesity ; diabetes mellitus ; metabolic ; comorbidities ; heart failure with preserved ejection fraction
cardiopulmonary exercise testing ; echocardiographic ; myocardial function ; left ventricular filling ; exercise
percutaneous ; coronary revascularization ; hemodynamically ; stable ; patient ; intensive care unit ; icu
secondary endpoints ; therapy ; atrial fibrillation ; atrial tachyarrhythmias ; atp ; shock therapy
speckle tracking echocardiography ; ste ; bivp ; acute ; right ventricular pressure overload ; rvpo
uptitration ; hr reduction ; bpm ; p value
lv fractional shortening ; lung ; incidence
functional enrichment analysis ; regulation ; cell death ; degs
dysfunction ; rad variant ; q66p ; congestive heart failure
systolic heart failure ; spironolactone ; hospitalization ; death
trastuzumab ; chf ; nontrastuzumab users ; hazard ratio
fontan failure ; circulatory ; hemodynamic ; portal hypertension ; cardiac output
perk ; scn5a ; kv4.3 ; mrna ; mrna splice
bottleneck stent ; myocardial infarction ; antiplatelet medication
ef ; bnp ; hf ; patients ; prognostic ; significance ; bnp ; ef
patients ; atrial fibrillation ; heart failure ; hf ; stroke ; anticoagulation ; patients
combination ; echocardiographic ; lv reverse remodeling ; sensitivity ; specificity
salt loading ; uninephrectomy ; ang ii infusion ; cardiac function ; hf
elevated ; mena expression ; correlates ; hf ; mena ; cardiac ; pathophysiology
differential effect ; lvef ; mortality ; hospitalization ; acute ; decompensated hf
outcomes ; patients ; atrial fibrillation ; early treatment of atrial fibrillation for stroke prevention trial
randomized ; follow-up
poc ; nps ; clinical
evidence ; intestinal ; patients ; chf
patients ; physicians ; readmission ; hospital
etiology ; comorbidities ; patients ; outcomes
proteins ; expression ; cardiac hypertrophy ; proteins ; nucleolin
combined training ; peak work rate ; peak quadriceps force
myocardial dd ; muscle ; titin hypophosphorylation
arni ; cardiovascular mortality ; hospitalization ; heart failure ; quality of life
patients ; exercise ; anaerobic metabolism ; peak respiratory quotient
evidence-based ; prognosis ; idiopathic dilated cardiomyopathy
fibrosis ; heart failure ; myocardial tissue ; left ventricular ; trichrome blue histologic analysis
kansas city cardiomyopathy questionnaire ; kccq ; hf with reduced ef ; patients ; hfpef
blood pressure ; arm cuff ; stroke volume ; ejection fraction ; end-diastolic volume ; echocardiography
patients ; biventricular support ; heartmate ii ; lvad ; centrimag ; right ventricular assist device ; rvad
tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; right ventricular contractile function ; prognosis
right ventricular ; rv ; prognosis ; patients ; heart failure ; hf
american college of cardiology ; american heart association ; patients ; ras ; patients ; ras
frailty ; prognostic ; heart failure ; hf ; biological phenotype
functional ms ; patients ; valve plasty ; degenerative mr ; dilated ; disease
implantable cardioverter-defibrillator ; physicians ; heart failure ; patients
eo-cfus ; cells ; functional capacity ; mortality ; nondiabetic ; patients
report ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
exercise ; training ; outcomes ; hf ; patients ; exercise ; training ; therapy ; clinical
ventricular assist device ; vad ; extracorporeal membrane oxygenation ; ecmo ; renal function
genotyped ; snp ; rs10927887 ; ka renal chloride channel gene ; clcnka
circulating progenitor cells ; cpcs ; endothelial ; prognostic ; cardiovascular diseases
hf-action ; correlation ; baseline ; hgb ; baseline ; hrqol ; kccq
pathological ; remodelling ; heart ; cardiac hypertrophy ; hf ; death ; fibrosis ; inflammation
nt-probnp ; plasma ; patients ; dyspnea ; left ventricular dysfunction ; admission
contractile function ; lv dilatation ; lv end-diastolic pressure ; wall stress ; lung
lv remodeling ; diastolic ; xo inhibition ; symptoms ; hospitalizations ; patients ; severe heart failure
costs
patients ; ef
blood pressure ; therapy ; patients ; ras
sdqt ; atrial pacing
btt ; dt ; btt ; patients
expenditure ; health ; income ; hf
ies ; crt-d ; heart failure ; death
clinical ; bnp ; inhospital ; mortality
t1-mapping ; myocardial ; heart failure
pharmaceuticals ; patients ; hfpef
β-blocker ; uptitrations ; patients ; hfref ; hfpef ; hospital ; admission
cardiac magnetic resonance ; amyloidotic ; diagnosis ; multiple myeloma ; osteomedullary biopsy
diagnosis ; hfpef ; clinical ; echo-doppler cardiography ; invasive haemodynamic assessment
dash ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure with preserved ejection fraction
vascular endothelial growth factor blockade ; beta-blocker ; therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
implantable cardioverter-defibrillators ; icds ; mortality ; cardiac resynchronization therapy ; crt ; symptoms ; mortality
patients ; frail ; frail ; biological phenotype
patients ; hfpef ; longitudinal ; cardiac event
patients ; lbbb ; implantable ; primary outcome ; primary outcome
standard error of measurement ; mdc ; clinical ; change
gene ; pathological ; heart disease ; transcription factors ; driving ; gene
patient ; emergency department ; acute heart failure ; ahf ; clinical
rm ; outcomes ; discharged ; admission ; heart failure
skeletal muscle ; sarcomere ; patients ; heart failure ; type 2 diabetes
qrs morphology ; cardiac resynchronization therapy ; crt
patients ; exercise-induced pasp ; pasp ; patients ; pasp
patients ; sst2 ; sst2 ; odds ratios ; cardiovascular events
mitochondrial complex v activity ; phosphocreatine ; atp
eplerenone ; patients ; hf-ref ; hyperkalemia ; patients
centrifugal flow pump ; hemocompatibility ; blood-flow ; pulse
physician ; outcomes ; patients ; outcomes ; medically ; diseases ; hf
heart rate ; ivabradine ; afterload ; patients ; systolic heart failure
meta-analysis ; biomedical ; biomedical ; patients ; dcm ; heart failure
cardiovascular outcomes in renal atherosclerotic lesions ; coral ; stenting ; ras
yorkshire ; implanted ; pacemakers ; ventricularly ; beats ; heart failure
echocardiographic ; patients ; reverse remodeling ; crt ; clinical ; outcomes
dietary approaches to stop hypertension ; dash ; mortality ; postmenopausal ; hf
therapeutic ; interatrial shunting ; patients ; heart failure with reduced ejection fraction
mortality ; heart failure ; hf ; implantable cardioverter defibrillators ; icds
heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical treatment ; heart failure
st2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ; hf
patients ; followed up ; composite primary outcome ; cardiovascular death ; stroke ; heart failure ; myocardial infarction
mi ; metoprolol ; elevated ; plasma norepinephrine ; dopamine ; elevated ; epinephrine
exercise-induced pasp ; clinical ; prognostic ; pulmonary hypertension ; patients ; right ventricular contractile reserve
patients ; implantable cardioverter-defibrillator ; heart function clinic ; university health network ; toronto ; canada
perk ; scn5a ; kv4.3 ; mrnas ; transient receptor potential cation channel m7 ; trpm7 ; mrna
cardiac-resynchronization therapy ; crt ; morbidity ; mortality ; chronic systolic heart failure ; wide qrs complex
antagonists ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; clinical ; outcomes ; chf
poc ; diagnostic
randomized ; medical
quality of life ; functional capacity
medline ; embase ; psycinfo
echocardiography ; cardiac ; cardiac function
patients ; lbbb ; qrs ; implantable
mortality ; readmissions ; costs ; patient ; physician ; hospital
international right heart foundation working group ; step ; syndrome ; right heart failure
hf ; hf ; epidemiology ; rheumatic fever
cardiac ; myocyte-specific mena overexpression ; cardiac ; pathology
symptoms ; hfpef ; diastolic filling time ; heart rate ; symptoms
medications ; patients ; heart failure and reduced ejection fraction ; outpatient
chronic heart failure ; hf ; hemodynamic ; syndrome ; dysfunction ; molecular pathways
exercise ; training ; exercise ; exercise capacity ; qol ; obese ; patients ; hfpef
risk stratification ; antiplatelet agents ; combination ; anticoagulants ; vascular diseases
patients ; systolic hf ; cxl-1020 ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke volume index
differential analysis ; cluster analysis
follow up ; ffm ; patients
therapeutic ; patients ; severe heart failure ; financial
cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
outpatient ; patients ; heart failure ; hospital ; discharge ; readmissions ; patient ; follow-up
primary endpoint ; intermacs ; interagency registry for mechanically assisted circulatory support
activate ; unfolded protein response ; upr ; scn5a ; remodeling ; hf
ankle-brachial index ; pulse-wave ; coronary artery calcium scores
myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous hf
fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; svr ; cardiac index
allopurinol ; lv contractile function ; xo-mediated ros ; myofilament ; sensitivity
baseline ; hgb ; correlated ; baseline ; kccq ; hgb ; exercise ; training ; hrqol
meta-analysis ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
patients ; left ventricular ejection fraction ; heart failure with preserved ejection fraction ; hfpef
prevalence ; clinical ; outcomes ; concentric left ventricular hypertrophy ; heart failure with preserved ejection fraction
patients ; heart transplant ; prospectively ; ecct
rate ratio ; therapy ; patient ; comorbidities
molecular pathways ; patients ; chronic heart failure ; chf
physical ; activity ; crf ; hf ; mortality
prognosis ; metabolic exercise ; cardiac ; kidney
heart failure ; compliance ; etidronate ; alendronate
rehospitalization ; medicare ; hospital ; medicare ; policy
physicians ; patients ; heart failure ; equitable ; therapeutic
multivariate logistic regression analysis ; bnp ; patients ; diastolic dysfunction
systolic function ; hfpef ; patients ; long axis function ; exercise
scn5a ; angii ; hypoxia ; expression ; upr ; downregulation
nt-probnp ; nonterminal epitopes ; central glycosylated region
receptors ; g-protein-coupled receptor ; kinase-2 ; downregulation
aas ; hf ; hyperkalemia ; hypokalemia ; spironolactone ; clinical
hf ; multivariate-adjusted odds ratio ; mortality ; hazard ratio ; mortality
placebo ; dopamine ; nesiritide ; secondary end points ; renal function ; clinical ; outcomes
follow-up ; patients
principal ; diagnostic ; clinical
implantable ; patients ; qrs duration
kccq ; patients ; hfpef
anemia ; medline ; cochrane library
hart ; patients ; hfpef ; hf with reduced ejection fraction ; hfref
bone morphogenetic protein 4 ; expression ; rrna transcription ; shift ; heterochromatic chromatin
left ventricular assist devices ; lvads ; patients ; heart failure ; incidence ; pump dysfunction ; pump
patients ; systolic hf ; the danish heart failure database ; esrd ; danish registry on dialysis
extracellular matrix ; left ventricular ; biopsies ; tissuefaxs ; correlated ; t1 time
elevated ; resistin ; biomarker ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
actin cytoskeleton ; mitochondrial function ; metabolism ; glycolysis ; gluconeogenesis ; citrate cycle
multivariable models ; st2 ; outcomes ; clinical ; amino-terminal pro-b-type natriuretic peptide
tachypacing-induced hf ; cxl-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
chemotherapy ; trastuzumab ; comorbidities ; chf ; international classification of diseases ; healthcare common procedure coding system codes
heart failure ; hf ; therapies ; outcomes ; patients ; hf ; preserved left ventricular ejection fraction ; lvef
change ; correlation ; hospitals ; longitudinal
sst2 ; sst2 ; odds ratio ; cardiovascular event
saxagliptin ; sitagliptin ; follow-up
t1 ; myocardial collagen ; myocardial
sprague-dawley ; randomized ; acf ; allopurinol
cardiac plasma membrane ; s1pr1 ; β1ar ; heart failure
neurohormones ; adipokines ; fat free mass ; ffm ; fat mass
fully magnetically levitated lvas ; mortality ; seattle ; heart failure
biomedical ; biomedical ; patients ; dcm ; heart failure ; pubmed
biventricular pacing ; bivp ; cardiac output ; cardiac ; surgery ; patients
myocyte hypertrophy ; heart failure ; global gene expression ; dna ; genomic
rule ; expression ; regulation ; rad ; q66p ; rgk protein ; in vivo
creatinine ; bnp ; furosemide ; dobutamine ; norepinephrine ; outcome
alphalisa ; immunoassays ; antibodies ; c termini ; nt-probnp
patients ; new york heart association ; nyha ; chronic heart failure ; reduced ejection fraction
catheter ablation ; patients ; compensated hfpef ; left ventricular ; ejection fraction
transplantation ; consultation ; consultation ; operation
deaths ; crt ; hazard ratio
cardiomyocytes ; myocardium ; conditions
therapy ; sst2 ; patients ; chronic heart failure
biventricular support ; rvads ; explanted
hno donor ; myocardial function ; evidence ; hf
tunel ; apoptotic cells ; tunel-positive cells
tapse ; pasp ; step ; rv function ; lv dysfunction
esrd ; outpatients ; systolic hf ; patients ; egfr
transitions ; readmission ; patients ; congestive heart failure ; south dakota
inpatient ; primary end point ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; cabg
cox proportional hazards models ; death ; transplantation ; lv assist device implantation ; heart failure ; hospitalization ; follow-up
exercise ; training ; outcomes ; chronic heart failure ; heart failure - a controlled trial investigating outcomes in exercise training ; hf-action
hospitalized ; heart failure ; saxagliptin ; sitagliptin ; antihyperglycemic drugs ; retrospective cohort study
intraclass correlation coefficient ; icc ; kappa coefficient ; standard error of measurement ; minimal detectable change ; mdc
nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity
biological phenotype ; clinically ; deficit index ; medical ; frailty
cardiology ; national cardiovascular disease registry practice innovation and clinical excellence registry
tachycardia ; intravenous ; atropine ; cardiac ; vagal tone
chf ; phenotype ; cardiac ; explant ; progenitors ; regulation
transitions ; training ; patients ; out-patient ; follow-up ; patient ; health care
surgically ; myocardial infarction ; heart failure ; randomized ; bisoprolol
sts ; hh ; medical ; all-cause mortality ; discharged ; patients ; heart failure
peritoneal dialysis ; pd ; diuretic ; volume overload ; heart failure ; hf
sdqt ; elevated ; acute ; β-adrenoceptor blockade ; esmolol
patients ; heart failure with preserved ejection fraction ; hfpef ; heart failure ; obese
peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; fontan circulation
readmission ; disease ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia
peripheral artery disease ; pad ; heart failure ; hf ; prevalence ; hf ; patients ; pad
regression analysis ; echocardiographic ; lv reverse remodeling ; lv end-systolic volume
renal dysfunction ; prognostic ; heart failure ; hf ; dysfunction ; end-stage renal disease ; esrd
report ; stable ; hno donor ; cxl-1020 ; myoctyes ; hearts ; patients ; heart failure ; hf
follow-up
poc ; frame ; patient ; consultation ; patients
shuttle walk test ; hand ; baseline
physician ; mortality ; internists ; cardiologists
histological ; capillary ; coronary perfusion
outcomes ; chronic heart failure ; hf ; exercise ; training
leaflet ; patient ; subvalvular ; annular ms
clinical ; outcomes ; heart failure ; charm ; candesartan in heart failure assessment of reduction in mortality and morbidity
interatrial shunting ; patients ; heart failure with reduced ejection fraction ; proof-of-principle cohort study
diagnosed ; heart failure ; left ventricular ejection fraction ; spironolactone ; kaiser permanente ; northern california
nicorandil ; heart rate ; aortic ; blood flow ; mitochondrial ; oxidative stress ; doxorubicin ; cardiotoxicity
aldosterone antagonist ; therapy ; chronic advanced heart failure ; patients ; post-myocardial infarction ; heart failure ; patients
myocardial extracellular matrix ; cardiac magnetic resonance ; t1 mapping ; pathobiology ; pathophysiology ; prognosis
physical examination ; patient ; bmi ; heart rate ; rhythm ; blood pressure ; auscultation ; rule ; valvular disease ; pulmonary congestion
preoperative ; renal dysfunction ; cardiovascular events ; stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass grafting
troponin t ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis risk in communities
evidence ; exercise ; cell senescence ; active ; osteoporosis
asymptomatic ; pediatric fontan ; patients ; catheterization
dyssynchronous nonfailing ; hf ; combinations ; remodeling
cell therapy ; chronic heart failure ; chf ; disease ; progenitor cells
anemia ; hf ; health-related quality of life ; hrqol ; hf
the lancet ; anoop shah ; air ; heart failure ; morbidity ; mortality
patients ; ventricular assist devices ; cardiac ; nurses ; gastrointestinal bleeding
american college of physicians ; acp ; evidence ; clinical ; anemia ; patients ; heart disease
extended criteria cardiac transplant ; ecct ; transplant ; donors ; transplant ; comorbidity
septum ; systolic ; lv posterior wall ; lv internal diameter ; metoprolol
patients ; hr variability ; mortality ; ami ; diagnosis ; chf ; lv dysfunction
bat ; n-terminal pro-brain natriuretic peptide ; hospitalized ; hf
prospective ; hf ; patients ; hf with reduced ef ; ef ; hfpef ; ef
tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
obese ; patients ; clinically ; stable ; hfpef ; exercise ; training ; peak vo2
patients ; acute rv failure ; chronic pulmonary arterial hypertension ; pah ; acute ; pulmonary embolism
baseline
ventricular ; wall stiffness
rad ; q66p ; cardiomyopathy
patients ; sst2 ; titrated ; cardiovascular event
resistin ; chemotherapy ; elevated ; cardiotoxicity
acute rv failure ; pulmonary embolism ; mortality ; diagnostic
use of exercise and medical therapies to improve cardiac function among patients with exertional shortness of breath due to lung congestion
tachycardic ; methylatropine ; vagal tone ; bradycardic ; propranolol ; sympathetic tone
outcomes ; mortality ; hospitalization ; mortality ; cardiovascular mortality ; hf ; hospitalization ; cox models ; exercise ; training
cox regression ; covariates ; spironolactone ; death ; hospitalization ; hyperkalemia ; acute kidney injury
mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity ; oxidative stress ; dna fragmentation
fractional flow reserve ; positron emission tomography ; ischemia ; bottleneck stenting ; left ventricle ; lad
cardiac resynchronization therapy ; crt ; mild heart failure ; hf ; patients ; qrs prolongation ; ejection fraction ; ef
neprilysin inhibitors ; natriuretic peptide ; atrial natriuretic peptide ; b-type natriuretic peptide
functional electrical stimulation ; peripheral muscles ; endothelial function ; clinical ; heart failure ; patients ; preserved left ventricular ejection fraction
uptitration ; renin-angiotensin system blocker ; beta-blocker ; therapy ; patients ; hospitalized ; heart failure ; preserved left ventricular ejection fractions
medicine ; patients ; dilated cardiomyopathy ; dcm ; heart failure
postoperative ; patients ; preoperative ; hypoalbuminemia ; albumin
nurse ; hospitalization ; physician ; discharge ; patients ; hospitalized ; heart failure
bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
baroreflex sensitivity ; heart rate variability ; hrv ; renal dnx
patients ; heart failure ; heart ; cardiologists ; cardiovascular ; surgeons ; medical ; patient
left bundle branch block ; remodeling ; dyssynchronous heart failure ; hf ; heart
hf-action ; randomized ; patients ; hf ; ejection fraction ; exercise ; training
hypertension ; diabetes mellitus ; grade ; systolic ; diastolic murmurs ; apex
tapse ; pasp ; downward ; hfref ; hfpef ; prognostic ; resolution
in vivo ; mir-25 ; antagomir ; cardiac dysfunction ; murine ; myocardium ; heart failure
cardioprotective ; nicorandil ; hemodynamic ; mitochondrial dysfunction ; administration ; doxorubicin
haematopoietic cell transplantation ; hct ; congestive heart failure ; chf ; anthracyclines
elevated ; nt-probnp ; admission ; all-cause mortality ; patients ; acute hf ; admission
epigenetic ; proteins ; histone acetyltransferases ; epigenetic ; histone deacetylases ; cardiac ; disease
carvedilol ; nonselective β-blocker ; selective β-blocker ; metoprolol ; thromboembolic events ; heart failure
baseline ; cardiac transplant ; ecct
hf ; ami ; pna ; mortality
patients ; heart failure ; hf ; evidence ; outcomes ; hf
remodeling ; arrhythmia ; ami ; hr variability ; arrhythmia
doxorubicin-induced cardiotoxicity ; resistin ; retn
patients ; hypertension ; compensated hfpef ; dash ; sodium
emd ; dyssynchronous hf ; remodeling ; insignificantly
diastolic dysfunction ; pathophysiology ; hfpef ; cardiovascular function
patients ; ejection fraction ; cardiac index ; inotropes ; medical ; transplant
high-density lipoprotein ; hdl ; endothelial cell ; nitric oxide
cohort study ; saxagliptin ; sitagliptin ; antihyperglycemic agents
differentially expressed genes ; degs ; ischemic heart failure ; healthy ; diagnosis ; heart failure
insulin resistance ; type 2 diabetes ; insulin receptor substrates 1 ; irs1 ; irs2 ; cellular metabolism
outcome ; admission ; discharge ; hospitalized ; heart failure ; hf ; nursing outcomes classification ; noc
8-fluo-camp ; phosphomimic ; ser77 ; ser83 ; riα ; proteins ; riα
multivariate analysis ; preoperative ; albumin ; mortality ; lvad ; implantation ; hazard ratio ; confidence interval
patients ; systolic heart failure ; qrs duration ; crt ; death ; hospitalization ; heart failure ; mortality
cox regression models ; propensity score ; oral ; glucocorticoid ; hf ; hospitalisations ; loop diuretics
functional electrical stimulation ; fes ; exercise capacity ; quality of life ; endothelial function ; chronic heart failure ; systolic function
dialysis ; patients ; hf ; hospitalization ; all-cause hospitalization ; mortality ; hf ; hospitalization ; death
adverse events ; reoperation ; bleeding ; driveline ; infection ; gastrointestinal bleeding ; stroke ; rankin score
beta blockers ; all-cause mortality ; readmissions ; heart failure with reduced ejection fraction ; hfref ; heart rate
dyssynchronous hf ; electromechanical delay ; emd ; myocyte depolarization ; myofiber shortening
qrs morphology ; outcomes ; cardiac resynchronization therapy ; resynchronization-defibrillation for ambulatory heart failure trial ; raft
biomarker ; clinical ; therapeutic
saf ; incidence ; liver ; nodularity
transplant ; patients ; pd ; hf ; clinical
frailty ; biological phenotype ; physical ; activity
crt-d ; patients ; ic ; crt-d ; ies
eds ; discharge ; patients ; heart failure ; outcomes ; driven ; readmissions
acute right heart failure ; therapy ; refractory cardiogenic shock ; heart ; extra corporeal membrane oxygenation ; ecmo ; cpr ; icu
report ; patient ; right atrial myxoma ; massive embolism ; pulmonary arteries ; surgically ; right atrial ; pulmonary embolectomy
emergency room ; undiagnosed ; heart disease ; symptoms ; hf ; surgical palliation
heart magnetic resonance imaging ; chelation ; patient ; compliance ; heart failure ; arrhythmias
ejection fraction ; ef ; patients ; nyha class iiib ; symptoms ; right ventricular dysfunction
cpcs ; early-outgrowth colony-forming units ; eo-cfus ; cells
gene expression ; bax ; pacing ; bcl-2 ; mrna ; expression ; heart failure ; bcl-2 ; bax
nitroxyl ; hno ; inotropic ; lusitropic ; vasodilator ; in vivo ; camp
therapy ; anticoagulation ; rate control ; cardiovascular ; complications ; stroke ; cardiovascular death ; acute heart failure ; patients ; atrial fibrillation
evidence ; clinical ; continuous-flow lvads ; heartmate ii ; hm ii ; heartware ; btt ; dt ; patients
patients ; baseline ; ef ; ef ; core
skeletal muscle ; lean mass ; z-score
dash ; mortality ; hf ; nonsignificant
quality of life ; all-cause mortality ; mortality
ef ; bnp ; bnp ; inhospital ; mortality
cardiovascular diseases ; heart failure ; hf ; incidence ; hf
heart failure ; left ventricular systolic dysfunction ; post hoc analysis
clcnka ; polymorphism ; rs10927887 ; p.arg83gly ; heart failure ; estimated glomerular filtration rate ; renastur
st2 ; functional capacity ; outcomes ; ambulatory ; patients ; hf
cardiac vegf expression ; endothelial no synthase activation ; hearts
gene expression ; cardiomyocytes ; jq1 ; drug ; genes
exercise-induced pasp ; right ventricular contractile reserve ; patients ; exercise-induced pasp
gene expression profile ; gse9128 ; gene expression omnibus ; non-ischemic heart failure ; ischemic
cardiac ; insulin-resistance ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose
baseline ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic ; invasively
psychosocial ; exercise ; outcomes ; heart failure ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
patients ; coronary angiography ; diagnosis ; systolic hf ; etiology ; ejection fraction
arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees ; ea
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic ; rhythm
cells ; angiotensin ii ; angii ; hypoxia ; scn5a ; mrna splicing ; scn5a
evidence ; hf with reduced ejection fraction ; hfref ; hf with preserved ejection fraction ; hfpef
extracorporeal life support ; therapy ; patients ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion ; therapy
heart failure ; reduced left ventricular ejection fraction ; fes ; exercise capacity ; quality of life ; endothelial function ; hfpef
expenditures ; hospitalizations ; noncardiovascular ; diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular ; drugs ; rate-control
intubation
raloxifene ; heart failure
hearts ; heart mass ; transgenic
patients ; hfref ; exercise ; respiratory gas analysis ; baseline
patients ; drugs ; heart failure ; biomedical ; nonprescribing ; patients
lean mass ; adverse outcome ; adipose tissue ; cardioprotective ; hf
hearts ; nucleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
patients ; chronic hf ; prevalence ; exercise ; hf ; hospitalization ; mortality ; exercise ; training
adverse event ; acute myocardial infarction ; congestive heart failure ; adverse events
macrophages ; cardiomyocytes ; doxorubicin ; in vitro ; resistin ; mrna ; protein expression
lvads ; heartmate ii ; thoratec corp ; pleasanton ; calif ; hvad ; heartware ; framingham
plasma nps ; adiponectin ; baseline ; ffm ; correlate ; nps ; adiponectin ; follow up
sympathetic tone ; parasympathetic tone ; heart rate ; intravenous bolus ; metoprolol ; atropine
hfpef ; pathophysiologically ; hf with reduced ef ; hfref ; hfref ; therapy
plasma ; collected ; hf ; patients ; immunoreactive ; nt-probnp ; c-terminally ; nt-probnp
qt interval ; ecgs ; baseline ; atrial pacing ; esmolol ; isoprenaline ; atropine ; infusion
confidence interval
power spectral analysis ; hf ; dnx
contractility ; ventricular-arterial coupling ; patients
change ; follow-up ; readmissions ; hospital ; follow-up
n-terminal pro-b-type natriuretic peptide ; nt-probnp ; misdiagnosis ; heart failure ; hf
cardiac magnetic resonance postcontrast t1 time ; prognosis ; hfpef ; postcontrast t1 ; biomarker ; hfpef
hf-action ; randomized ; patients ; left ventricular ejection fraction ; new york heart association class ii ; hf ; exercise ; training
myocardial dd ; collagen deposition ; titin ; obese ; diabetic ; zsf1 ; heart failure with preserved ejection fraction
cardiac ; jq1 ; bet ; pathological ; cardiac ; gene expression
cox-proportional hazard models ; negative binomial regression models ; health
systolic blood pressure ; elevated ; left ventricular ; hypertrophy
hand2 ; hypertrophy ; fibrosis ; ventricular dysfunction ; gene
admission ; nt-probnp ; patients ; acute hf ; diagnosis
peak oxygen consumption ; vo2max ; resting hr ; bpm ; p value
follow-up ; patients ; combined end point ; death ; heart failure ; death ; cardiac transplant
frailty ; health abc short physical performance battery ; habc battery ; gill index ; hf
epigenetic ; cardiac ; cardiac ; gene ; signal transduction ; pathological ; gene expression ; hf
clinical ; rule ; patients ; cad ; angiography ; patients ; systolic hf ; cost
chronotropic response ; heart rate ; exercise ; baseline ; follow-up ; tests ; heart rate ; exercise
patient ; hospital ; gastrointestinal bleeding ; patient ; ventricular tachycardia ; terminal heart failure
percutaneous ; revascularization ; angioplasty ; stenting ; clinical ; patients ; randomized ; clinical
patients ; hf ; t2d ; erc ; vo2max ; maximum oxygen consumption ; skm ; biopsies
mild hf ; qrs prolongation ; lvef ; crt ; reverse remodeling ; clinical ; systolic dysfunction
patients ; rv support ; lvad ; patients ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
follow-up ; patients
frailty ; gill index ; hf
prevalence ; hf ; ami ; adjusted odds ratio
chronic heart failure ; chf ; multisystem disease ; comorbidities ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
chronic ; β-ar ; catecholamine ; infusions ; pde2 ; expression ; camp ; activity ; correlated ; cardiac ; β-ar responsiveness
chronic pah ; clinical ; hospitalized ; patients ; acute ; rv decompensation ; pharmacologic ; therapies ; rv failure ; pah
obese ; zsf1 ; heart failure with preserved ejection fraction ; lung ; preserved left ventricular ejection fraction ; left ventricular dd
xanthine oxidase ; xo ; left ventricular ; myocytes ; volume overload ; vo ; mitral regurgitation ; aortocaval fistula ; acf
pulse ; myocardial t1 ; heart failure
symptomatic ; new york heart association classes ; saf
clinicians ; patients ; patient ; clinician ; medication ; patient
patients ; physicians ; mortality ; physicians ; hospitals
western ; administrative ; health ; patients ; hf ; hospitalized ; ami
report ; connection ; patients ; disease ; healthcare ; conditions ; turkey
retrospective cohort ; eds ; diagnosis ; heart failure
outcome ; prospective ; hospitalized ; hf ; nursing ; outcomes
mirnas ; rnas ; expression ; genes ; messenger rna ; repression
patients ; hfpef ; ivabradine ; placebo ; double-blind
cardiac ; cells ; cardiac ; cells ; cardiac functions ; myocardial infarction
nps ; adverse outcomes ; patients ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
nurses ; pathophysiology ; hf ; nursing ; medical ; symptoms ; pathophysiologic
outcome ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia ; pna
mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
jq1 ; bets ; chromatin ; downstream signalling ; rna ; polymerase ii ; pol ii
catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction ; hfpef
epidemic ; heart failure with preserved ejection fraction ; hfpef ; patients ; health ; symptoms ; quality of life
multivariate cox proportional hazards regression modeling ; hospitalization ; acute coronary syndromes ; coronary interventions ; patients
cyclic adenosine monophosphate ; camp ; cyclic guanosine monophosphate ; cgmp ; hearts
ra ; methotrexate ; tnf antagonist ; non-biological disease modifying antirheumatic drug ; nbdmard
intestinal dysfunction ; intestinal ; lead ; chronic ; inflammatory ; catabolic ; anabolic ; cardiac cachexia ; terminal ; chf ; prognosis
report ; patient ; diagnosis ; ischemic-hypertensive cardiomyiopathy ; angina ; myocardial ischemia ; coronary arteries
sphingosine-1-phosphate receptor 1 ; s1pr1 ; β1-adrenergic receptor ; β1ar ; g-protein-coupled receptors ; heart
septal ; correlated ; pcwp ; p values
therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
bradycardia ; intravenous ; metoprolol ; cardiac ; sympathetic tone
randomized ; walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; severe heart failure
outcomes ; patients ; prescribed ; pharmacological ; discharge ; left ventricular function
gls ; lvef ; prognostic ; clinical ; echocardiographic ; systolic
erc ; dapc protein ; sarcomeric microstructure ; skm ; myofibre regeneration
micrornas ; expression ; bhlh ; transcription factor ; hand2 ; myocardium ; gene ; heart failure
rad ; q66p ; rad ; cav1.2 ; cav1.3 ; l-type channel ; isoforms ; heart
ef ; lcx ; lad ; stenting ; infarcted ; left ventricle ; lcx ; lad
lv compliance ; lv end-diastolic volume ; lv end-diastolic pressure ; β coefficient
mva ; surgical ; implantation ; leaflet ; leaflet ; edge-to-edge anastomosis
hart ; patients ; new york heart association ; nyha ; hospitalized ; hf ; primary outcome ; death ; hf ; hospitalization
in vivo ; cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
bet ; bromodomain proteins ; bets ; acetyl-lysine reader proteins ; hf ; pathogenesis ; hf
blood transfusions ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
grade ; clinical
hf ; hospitalization
right heart circulatory failure ; disease ; right heart
ventricular action potentials ; excitation-contraction ; myocardium
ivabradine ; exercise capacity ; left ventricular filling ; patients ; heart failure with preserved ejection fraction ; hfpef
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; patients ; systolic dysfunction
univariate analysis ; bnp ; estimated glomerular filtration rate ; hypertension ; transmitral ; e-wave ; diastolic mitral annular velocity
at1 receptors ; neprilysin ; renin-angiotensin-aldosteron ; ras ; vasodilatory ; diuretic ; natriuretic peptides
β-blockade ; halt ; disease ; protein kinase ; pka ; β-adrenergic receptor
evidence ; erythropoiesis-stimulating agent ; therapy ; venous thromboembolism
multivariable adjustment ; mortality ; hospitalization ; hazard ratio ; cardiovascular mortality ; hf ; hospitalization
percutaneous ; chronic myocardial ischemia ; stent ; polytetrafluoroethylene
clinical ; genetic ; chf ; area under the curve ; auc ; genetic ; auc ; clinical ; auc
multivariable logistic analysis ; peak oxygen uptake ; metabolic exercise ; cardiac ; kidney ; prognostic ; hf index
heart failure ; hf ; tumor necrosis factor ; tnf ; tnf antagonists ; disease ; severe hf
centers for medicare and medicaid services ; cms ; hospital ; outcomes ; reported ; mortality ; readmission ; penalties
cox proportional hazard models ; covariates ; follow-up ; physician ; discharge ; primary outcome ; death ; all-cause readmission
multivariate logistic regression analysis ; rule ; cad ; stenosis ; 3-vessel cad ; 2-vessel cad ; left anterior descending artery
activate ; signal transduction ; transcription factors ; pathological ; cardiomyocytes ; transcription factors ; epigenetic ; chromatin structure
patients ; hypertensive hfpef ; dash ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular dilatation
randomized aldactone evaluation study ; symptomatic chronic advanced heart failure ; patients ; aldosterone antagonist ; spironolactone ; mortality ; placebo
incidence ; mortality ; outcomes ; heart failure ; acute myocardial infarction ; patients ; acute myocardial infarction ; western australia
chf ; hct ; polymorphisms ; genes ; anthracycline ; metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication
pathophysiological ; diagnostic ; prognostic
lvad ; surgery ; patients ; albumin ; hypoalbuminemia ; surgery
multivariate model ; creatinine ; hazard ratio ; confidence interval ; mortality
death ; patients ; estimated glomerular filtration rate ; odds ratio ; confidence interval
clinical ; hm ii ; heartware ; patients ; economic ; hm ii
dopamine ; nesiritide ; renal function ; patients ; acute heart failure ; renal dysfunction
randomized ; hr variability ; hr variability ; clinical ; risk stratification ; cardiac ; patients
complications ; implantation ; lvad therapy ; transplantation ; btt ; dt ; medical therapy
clinical ; artery tonometry ; prospectively ; admission ; patients ; icu ; clinical
fully magnetically levitated centrifugal-flow chronic lvas ; adverse event ; quality of life ; functional status
signalosome complex ; scaffold protein ; drives ; kinases ; phosphorylation ; effector molecules
breast cancer ; patients ; medicare ; diagnosed ; breast cancer ; chemotherapy ; seer-medicare ; texas ; medicare
ejection fraction ; b-type natriuretic peptide ; patients ; hospitalized ; heart failure ; inhospital ; outcomes ; get with the guideline-heart failure registry
diseased ; cardiomyocytes ; pde2 ; activity ; cgmp synthesis ; nitric oxide ; donors ; pde2 inhibition ; β-ar responsiveness
l-dko ; cardiac ; irs1 ; irs2 ; proteins ; heart failure ; cardiac energy metabolism gene expression ; p38α ; mitogen-activated protein kinase ; p38
ecs ; hdl ; phosphorylation
pasp ; 6-minute walking distance ; peak o2
rcts ; patients ; sts ; hh ; sts
ventricular myocytes ; sarcomere ; shortening
administrative ; alberta ; discharged ; hospital ; diagnosis ; heart failure
heart failure ; histologically ; myocardial collagen ; healthy ; heart failure
covariates ; crt ; death ; hf ; hospitalization ; hazard ratio ; lvef
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor 1 ; s1pr1 ; downregulation ; cardiac ; hypertrophic ; heart failure ; s1pr1 ; cardiac ; gene ; therapy
relative risk ; rr ; heart failure ; bisphophonates ; rr ; confidence interval ; hazard ratio
medicare ; centers for medicare and medicaid services ; clinics ; propensity-score
physician ; heart failure ; clinical practice guideline ; cpg ; outcomes ; heart failure ; hf
nicorandil ; heart failure ; hemodynamic ; mitochondrial dysfunction ; antitumor ; activity
kccq ; new york heart association class ; patients ; hfpef ; hf with reduced ef
rhythm control therapy ; diagnosis ; atrial ; sinus rhythm ; rhythm control ; symptoms ; rate control
acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic ; therapy
hf ; prospective ; dual-energy x-ray absorptiometry ; echocardiography ; blood
patients ; heart failure
acp ; red blood cell transfusion ; hemoglobin ; hemoglobin ; hospitalized ; patients ; coronary heart disease
hospitals ; patients ; hospitalized ; heart failure ; hf ; conditions ; acute myocardial infarction ; pneumonia ; conditions
implanted ; interatrial shunt ; clinical ; haemodynamic ; outcomes ; patients ; heart failure with reduced ejection fraction
t1 time ; correlated ; right ventricular-pulmonary arterial coupling ; pulmonary vascular resistance ; right ventricular ejection fraction
left ventricular assist devices ; lvads ; chronic end-stage heart failure ; bridge to transplantation ; btt ; patients ; destination therapy ; dt
exercise ; training ; peak oxygen consumption ; quality of life ; obese ; patients ; heart failure with preserved ejection fraction ; randomized ; clinical
carvedilol ; metoprolol ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
oral ; glucocorticoids ; hf
ivabradine ; ea ; tac ; placebo
carvedilol ; therapy ; metoprolol ; hazard ratio ; confidence interval
follow-up ; systemic ; adverse events ; patients ; dcm ; heart failure
testosterone supplementation ; exercise rehabilitation ; health ; outcomes ; patients ; chf ; testosterone
change ; peak vo2 ; correlated ; change ; lean body mass ; change ; thigh ; muscle
hospitals ; get with the guidelines-heart failure ; hf ; patients ; ef ; ef ; ef ; ef
tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
hfpsi ; death ; medical ; hospitalization ; hf ; clinic ; outpatients ; hf ; health
cardiac ; insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; hypertrophy ; heart failure
multivariate cox model ; pasp ; exercise ; peak o2 ; prognostic ; hazard ratio ; peak o2 ; pasp
pathophysiology ; heart failure with preserved ejection fraction ; hfpef ; myocardial extracellular matrix
combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular ; dilatation
breathing ; cardiac arrest ; advantage ; pulseless ventricular fibrillation ; pvf ; implanted ; cardioverter-defibrillator device
rad ; rgk ; rem ; rem2 ; rad ; monomeric g proteins ; ventricular action potential ; gain ; cardiac ; l-type channel ; activity
acetylcholinesterase inhibitor ; pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; hf ; myocardial infarction
cardiac sympathetic activity ; β-blocker
evidence-based ; heart disease ; therapies ; patients ; cabg ; sweden
lvef ; clinical ; reverse remodeling ; death ; hf ; hospitalization ; hazard ratio
patients ; brain natriuretic peptide ; bnp ; bnp ; patients ; bnp ; bnp
outcomes ; coprimary end points ; end point ; change ; serum cystatin c ; renal function ; end point
tapse ; longitudinal rv fiber shortening ; pasp ; rv ; in vivo ; rv ; prognosis
pde ; pde2 ; cgmp ; leading ; camp hydrolysis ; cross talk ; cgmp ; camp signaling
n-terminal probnp ; nt-probnp ; midregional proanp ; mr-proanp ; adiponectin ; elevated ; chf ; correlated ; bmi
re-hospitalization ; admissions ; patient
peptides ; szeto-schiller ; ss ; ss20 ; cardiac function ; proteomic remodeling ; signaling pathways
clinical ; cardiac arrest ; cardiopulmonary resuscitation ; cpr ; diagnosis ; posterior wall infarction ; hospitalized ; cardiac
incidence ; hyperkalemia ; mineralocorticoid receptor antagonists ; mineralocorticoid receptor antagonists ; heart failure ; hf
grade ; evidence ; acp ; erythropoiesis-stimulating agents ; patients ; anemia ; congestive heart failure ; coronary heart disease
patients ; patients ; type 2 diabetes ; therapy ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; insulin
upr ; scn5a ; ventricular systolic hf ; human induced pluripotent stem cell-derived cardiomyocytes ; hipsc-cms
ambulatory ; patients ; heart failure ; hf ; reduced ejection fraction ; renin-angiotensin system ; ras ; β-blockers ; all-cause mortality ; readmissions
financial ; cochrane effective practice and organisation of care taxonomy
copd ; chf ; crf ; icc ; kappa coefficients
patients ; stable heart failure ; left ventricular ejection fraction ; training ; training
patient ; implantable cardioverter-defibrillator ; implant ; change ; clinical
patients ; heart failure ; myocardial function ; dilated ; contracting ; ventricles ; aetiologies
patients ; implantable cardioverter-defibrillator ; patients ; implantable cardioverter-defibrillator
global left ventricular longitudinal systolic strain ; gls ; left ventricular ; cardiovascular ; atrial fibrillation
rad ; q65p ; murine ; rad ; q66p ; l-type currents ; cav1.2 ; cav1.3 ; wild-type rad
patient ; mi ; hazard ratios ; hf
medicare ; patients ; acute ; hospital ; hf ; ami ; pna
cardiovascular events ; baseline ; sst2 ; metoprolol succinate
ctnt ; nt-probnp ; aric ; hf ; aucs ; nris
hf ; hf with reduced ef ; hf with preserved ef ; change ; hf ; mi
hdl ; nyha-iiib ; phosphorylation ; phosphorylation ; hdl ; healthy
carvedilol ; von willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
heart failure ; hf ; hypertensive heart disease ; hhd ; pathophysiology ; therapeutic ; hhd ; stable ; phenotypes
sarcoplasmic reticular ; protein ; phospholamban ; infarcted ; hearts ; metoprolol
tug ; patients ; chronic obstructive pulmonary disease ; copd ; chronic heart failure ; chf ; chronic renal failure ; crf
exercise ; intramuscular testosterone supplementation ; patients ; chronic heart failure ; chf ; testosterone ; collected ; health ; outcomes
patients ; hospitalized ; hf ; preserved lvef ; mortality ; patients ; lvef ; lvef ; mortality
gls ; left ventricular ejection fraction ; lvef ; systolic mitral annulus velocity ; multivariate models
heart failure ; hf ; plasma b-type natriuretic peptide ; bnp ; preserved ejection fraction ; ef ; hf
rm ; telemonitoring ; implanted ; medical ; structured telephone support ; sts ; human-to-human contact ; hh ; human-to-machine interface
cox regression analysis ; patients ; beta-blockers ; beta-blockers ; primary endpoint ; therapy ; antitachycardia pacing ; atp ; shock therapy
ethically ; legal ; decisions
patient ; prescribing ; medications ; medical
cost ; patient ; rhythm-control ; rate-control
left ventricular ejection fraction ; egfr
crf ; hazard ratios ; body mass index ; obese
primary outcome ; patients ; crt ; hazard ratio ; confidence interval
hfpsi ; blood urea nitrogen ; b-type natriuretic peptide ; new york heart association class ; diabetes ; atrial fibrillation ; all-cause hospitalization
medicare patient safety monitoring system ; mpsms ; adverse event ; patients ; hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
cells ; functional capacity ; cells ; peak vo2
outpatients ; heart failure and reduced ejection fraction ; patient
case-fatality rate ; patients ; hf ; hf ; case-fatality rate
frame ; chf ; anthracycline ; stem cell ; allogeneic ; autologous ; follow-up
resting tension ; fpassive ; muscle ; kcl-ki ; titin ; titin ; extracellular matrix ; fpassive
heart failure ; myocardial infarction ; mi ; β-adrenoceptor blockade ; infarcted ; metoprolol
training ; exercise capacity ; muscle ; quality of life ; cardiac ; nt-probnp ; inflammatory ; il6 ; hscrp ; biomarkers
hospital ; readmission ; all-cause readmission ; acr ; potential preventable readmission ; ppr ; medicare ; medicaid ; readmission ; cms
congestive heart failure ; correlation coefficient
exercise ; rehabilitation ; walking ; minnesota quality of life ; exercise
arginine vasopressin ; avp ; physiologic ; chf ; avp ; vasopressin receptor antagonist ; therapy ; therapeutic ; chf
angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; β-blockers ; patients ; heart failure and reduced ejection fraction
therapies ; medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; risk stratification ; patient ; heart failure ; therapies ; disease
dietary approaches to stop hypertension ; dash ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hfpef
right ventricular pacing ; gene expressions ; bax ; bcl-2 ; caspase-3 ; rtq-pcr ; interventricular septum ; biopsies ; heart failure
hearts ; caspase-3 ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; bax ; caspase 3 ; expression
metoprolol ; carvedilol ; sympathetic activity ; von willebrand factor
acute hf ; relax-ahf ; astronaut ; pronto ; patient ; patients ; end points
hospitalized ; hf ; international classification of diseases ; clinical ; principal ; discharge ; diagnosis
pulmonary capillary wedge pressure ; baseline ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
rad ; q65p ; movement ; wild-type rad ; q65p ; l-type channel ; rgk proteins
ss20 ; heart failure ; proteomics ; actin cytoskeleton ; ss20 ; mitochondrial ; metabolic pathways
aortic insufficiency ; mechanical circulatory support ; continuous flow ; left ventricular assist devices ; lvads ; pulsatile devices
administration ; pyridostigmine ; coronary artery ligation ; cardiac ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; hf
discharge ; patients ; follow-up ; physician ; physician
life expectancy ; heart failure ; patients ; disease ; terminal heart failure
heart failure ; discharges ; university of connecticut health center ; patients ; follow-up
outcomes ; patients ; new york heart association ; nyha ; heart failure ; eplerenone ; placebo ; heart failure ; medicines ; emphasis-hf
echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; ivc occlusion ; bivp ; ste ; rs
evidence ; drugs ; drugs ; raas ; renin inhibitors ; endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ; hf ; pharmacologic ; therapeutics ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
in vivo ; hf ; phenylephrine ; haemodynamic ; surgical ; transverse aortic constriction ; tac ; jq1 ; pathological ; cardiac hypertrophy
muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; fontan
cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
acute myocardial infarction ; ami ; incidence ; deaths ; heart failure ; hf ; ami
h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; cardiac metabolic gene expression ; atp
bottleneck stent ; implanted ; lad ; circumflex artery ; lcx ; lcx ; lad
hospitalized ; heart failure ; dipeptidyl peptidase-4 ; dpp-4 ; antihyperglycemic agents
cox modeling ; heart failure patient severity index ; hfpsi ; university of michigan ; hf ; clinic ; primary outcome
pde2 ; healthy ; cardiomyocytes ; camp ; inotropic effect ; acute ; β-ar ; contractility
atp ; shock therapy
cardiac resynchronization therapy ; crt ; patients ; heart failure ; hf ; outcomes ; crt ; dialysis ; reported
joint ; cardiorespiratory fitness ; crf ; body mass index ; heart failure ; hf ; mortality ; cardiovascular ; hf ; mortality
eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; eplerenone ; patients ; hospitalization ; heart failure
heart rate ; cardiac ; patients ; patients ; acute myocardial infarction ; ami ; patients ; congestive heart failure ; chf ; left ventricular ; dysfunction
ventricular cardiomyocytes ; chronic ; insulin ; irs1 ; irs2 ; proteins ; insulin ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
echocardiograms ; left ventricular ; midpapillary ; atrioventricular delay ; avd ; interventricular delay ; vvd ; ste ; circumferential strain ; radial strain ; rs
patients ; new york heart association ; nyha ; functional class ; hf ; ejection fractions ; chronic ; stable ; guideline-directed medical therapy ; gdmt ; united states ; canada ; europe
patients ; qrs ; hazard ratio ; primary outcome ; patients ; qrs ; hazard ratio
dyssynchronous hf ; myofiber shortening ; septum ; myofiber shortening ; stretch ; wall
proteomics ; proteomics ; transverse aortic constriction ; tac ; heart failure ; signaling pathway ; ingenuity pathway analysis
cells ; transforming growth factor-β ; tgf-β ; epithelial ; mesenchymal ; transition ; expression ; pluripotency markers
pka ; change ; riiα ; cα ; expression ; riiα ; ser96 ; cα ; thr197 ; phosphorylation ; hf
patients ; hfref ; left ventricular ejection fraction ; hfpef ; left ventricular ejection fraction ; β-blocker ; hf ; hospitalization
cross talk ; g-protein-coupled receptors ; physiological ; significance ; regulation ; hearts ; chronic ; β-adrenergic receptor ; postischemic heart failure
concentric remodeling ; concentric hypertrophy ; left ventricular ; remodeling ; heart failure with preserved ejection fraction ; hfpef ; eccentric hypertrophy ; patients
exercise ; exercise
rv dysfunction ; hazard ratio ; confidence interval ; cachexia ; hazard ratio ; multivariate analyses
patients ; resting hr ; follow-up ; baseline ; vo2max ; patients ; resting hr ; p value
tgf-β ; cell ; phenotype ; in vitro ; cardiac progenitor function ; cell ; clinical
nt-probnp ; inflammatory ; biomarkers ; hscrp ; il6 ; patients ; hscrp
bets ; in vitro ; neurohormonally ; heart disease ; nanomolar ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological ; gene induction
bat ; functional status ; quality of life ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; heart failure ; hospitalizations ; patients ; nyha functional class iii ; hf
elevated ; p70s6k ; pkc-βii ; hdl ; nyha-iiib ; malondialdehyde ; bound ; hdl ; nyha-iiib ; hdl ; healthy
change ; exercise ; exercise
dnx ; dnx
habc battery ; hf ; health abc hf model ; death
ejection fraction ; patients ; frail ; biological phenotype ; death ; frailty ; deficit index ; death
hemoglobin ; hgb ; hrqol ; hrqol ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
atrial fibrillation ; congestive heart failure ; health care ; expenditures ; patients ; québec ; randomized ; rhythm ; rate-control
heart failure ; patient ; compliance ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
report ; calcineurin ; nfat ; mir-25 ; expression ; basic helix-loop-helix ; bhlh ; transcription factor ; dhand ; hand2 ; diseased ; myocardium
exercise ; correlated ; psss ; btes ; exercise ; psss ; btes
nt-probnp ; admission ; sensitivity ; specificity ; confidence interval ; area under the curve
prognostic ; r-r interval ; hr variability ; short-term fractal scaling exponent ; prognostic
diastolic function ; diastolic filling formalism ; relaxation ; doppler mitral inflow velocity ; e-wave
heart failure ; hf ; patients ; spontaneous ventricular tachycardia ; hf ; patients ; spontaneous vt ; hearts
gls ; cox model ; chronic heart failure ; hypertension ; diabetes ; stroke ; estimated glomerular filtration rate ; lvef
patient ; vad ; patients ; ventricular assist device ; ecmo ; patients ; extracorporeal membrane oxygenation ; ecmo ; vad ; patients ; ecmo ; vad
ischemic events ; ies ; patients ; ischemic cardiomyopathy ; ic ; cardiac resynchronization therapy ; defibrillator ; crt-d
heart failure ; disease ; evidence-based ; health care
resistin ; heart failure ; murine ; resistin ; transgenic ; retn ; gene ; resistin
patients ; angiotensin-converting enzyme inhibitors ; angiotensin receptors blockers ; β-blockers
cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ; tac
resynchronization-defibrillation for ambulatory heart failure trial ; implantable ; primary end point ; all-cause mortality ; heart failure ; hospitalization
heart failure ; patients ; italy ; confirmatory factor analysis ; cfa ; schfi v.6.2 ; self-care maintenance ; self-care management ; self-care confidence
functional status ; 6-mwt ; nyha class ; patients ; hfpef ; hfref ; prescribed ; therapy ; patients ; hfpef ; death ; hf ; hospitalization
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; follow-up ; mortality ; ischemic cardiomyopathy
scaffold proteins ; cardiac remodelling ; field ; therapeutic
patients ; chf ; testosterone ; exercise ; testosterone ; placebo
functional ms ; lv dilatation ; heart failure ; hf ; functional ms ; hf ; prolapse ; degenerative mitral valve
new york heart association class ; kccq ; symptom ; spearman correlations ; 2-way anova ; patients ; hf with reduced ef ; hfpef
prescribing ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; patients ; heart failure ; medications ; medical
ang ii infusion ; ang ii infusion ; uninephrectomy ; ang ii infusion ; salt loading ; ang ii infusion ; uninephrectomy ; salt loading
transmitral blood flow velocity ; tissue doppler ; diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcwp ; patients ; decompensated systolic heart failure ; hf
systolic ; lv ejection fraction ; lv strain ; strain ; systole ; diastolic ; lv strain rate ; diastole ; transmitral flow ; patients ; sinus rhythm ; follow-up
peak vo2 ; exercise
hazard ratios ; confidence interval ; hf ; hf
ami ; patient ; hospital ; hospital compare ; p-value
mass spectrometry ; c-terminally ; nt-probnp ; physiological ; proteolysis
ctnt ; nt-probnp ; report ; ctnt ; nt-probnp ; clinical ; hf
hfpef ; patients ; new york heart association class ii ; ejection fraction ; fes ; placebo
left ventricular ; systolic pressure ; ejection fraction ; fractional shortening ; cardiac output ; lv end-diastolic pressure ; mi ; metoprolol
baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction ; clinical ; carotid ; baroreflex activation therapy ; bat ; heart failure ; hf
outcome ; hazard ratio
hf ; blood glucose ; obesity ; systemic hypertension ; rheumatic fever ; disease
hazard ratios ; crf ; obese ; body mass index
kccq ; patients ; hfpef ; log rank ; ef
baseline ; egfr ; egfr ; egfr ; hypertension ; diuretics ; esrd
myocardial ; phosphodiesterase-2 ; pde2 ; heart failure ; hf ; beta-adrenergic receptor ; β-ar ; healthy ; diseased ; cardiomyocytes
heart failure ; patients ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator ; carvedilol ; atp ; shock therapy ; metoprolol
epicatechin-rich cocoa ; skm ; mitochondrial structure ; taub ; ramirez-sanchez ; ciaraldi ; perkins ; murphy ; naviaux ; hogan ; ceballos ; maisel ; henry
follow-up ; death ; readmission ; patients ; physician ; physicians
mena overexpression ; tac ; surgery ; mena ; cardiac hypertrophy ; cardiac
echocardiography ; lv end-diastolic volume ; mitral valve opening ; mva
pd ; diuretic ; hf ; outcomes ; clinical ; hospitalizations ; pdrelated ; complications
atp ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial ; glycolysis
patients ; eplerenone ; potassium ; potassium ; hospitalization ; hyperkalemia ; medication ; adverse events
patient ; new york heart association class iii ; heart failure ; hf ; left ventricular ejection fraction ; periodic breathing ; pb ; report
implantation ; bottleneck stent ; lad ; lcx ; myocardial ischemia ; stent ; ischemic heart failure ; stent ; therapeutic
potassium ; spironolactone ; aas
obese ; body mass index ; chronic ; stable ; hfpef
proangiogenic ; vegf pathway ; intravenously ; injected ; adenoviral ; vegf receptor ; adenovirus
surgical ; post-lvad ai ; aortic valve ; leaflet ; bioprosthetic aortic valve replacement ; functional capacity ; lvad ; patients ; symptomatic
exercise-induced pulmonary artery systolic pressure ; pasp ; stress doppler echocardiography ; right ventricular contractile reserve ; patients ; pulmonary hypertension ; right heart failure
medline ; embase ; healthstar ; cinahl ; cochrane library ; campbell collaboration ; joanna briggs institute evidence based practice ; centre for reviews and dissemination ; evidence based practice centres
mixed-methods study ; health care ; systolic heart failure ; prescribed ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ; angiotensin receptor blockers ; angiotensin converting enzyme inhibitors ; beta receptor blockers ; mineralocorticoid receptor antagonists
chest ; rs ; rs synchrony ; ste ; noninvasive ; rvpo ; rs synchrony ; strain ; bivp
tapse ; pasp ; tapse ; pasp ; cox regression ; kaplan-meier analyses ; tapse ; pasp
symptom ; cpet ; patients ; chf ; patients ; exercise ; exercise ; patients ; exercise ; rehabilitation
heart failure ; hf ; mrna splicing ; cardiac ; scn5a ; endoplasmic reticulum
heart failure ; diagnosis ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; disease
tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; clinical ; evidence-based ; medications ; costs ; outcomes
natriuretic peptides ; nps ; b-type np ; n-terminal pro-b-type np ; diagnosis ; acute heart failure ; patients ; emergency department ; acute dyspnea
peak oxygen consumption ; peak vo2 ; exercise ; exercise oscillatory ventilation ; eov ; partial pressure of end-tidal co2 ; petco2 ; gain ; cardiopulmonary exercise testing
retrospective cohort study ; denmark ; bisphosphonates ; raloxifene
hypertension ; lv dilatation ; lv dysfunction ; mitral valve ; organic ; lesion ; systolic ; diastolic tethering ; etiology
tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; patients ; diuretic ; therapy ; serum sodium ; systolic function
longitudinal ; strain ; left ventricle ; echocardiographic ; patients ; baseline ; echocardiography ; crt ; follow-up ; echocardiograms
platelet-activating factor ; paf ; metabolic ; enzymes ; follow-up ; patients ; diagnosed ; heart failure ; hf ; healthy
acute care surgery ; acs ; consultations ; oht ; transplantation ; medical therapy ; intravenous ; inotropes ; ventricular assist devices ; vads
patients ; hfpef ; ivabradine ; exercise capacity ; left ventricular filling pressure ; exercise ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
renin-angiotensin-aldosterone system ; raas ; hfref ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; evidence ; hfpef
admission ; lvet ; patients ; outcome ; tonometric
heart rate ; blood pressure ; renal function ; spironolactone ; ras blockers ; β-blockers
cardiac ; β-adrenoceptor blockade ; heart failure ; reverse ; cardiac remodeling ; elevated ; plasma catecholamines
rate ratio ; confidence interval ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; therapy ; confidence interval ; β-blockers ; therapy
ss31 ; congestive heart failure ; phenotypes ; mitochondrial ; tac ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein
myofibrillar ; atpase ; activity ; mrna ; phospholamban ; α-myosin heavy chain ; mrna ; β-myosin heavy chain ; metoprolol
hdl ; healthy ; hdl ; healthy ; patients ; chf-nyha-iii ; hdl ; nyha-iiib ; patients ; chf-nyha-ii ; hdl ; nyha-ii
anesthetized ; coronary microembolization-induced hf ; cxl-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; maximal ventricular power index
standard error of measurement ; mdc ; mdc
baseline ; heart failure ; t1-mapping ; administration ; administration
etiologies ; hf ; idiopathic dilated cardiomyopathy ; ischemic ; valvular
st2 ; functional capacity ; clinical ; outcomes ; ambulatory ; patients ; hf ; heart failure ; outcomes ; exercise ; training ; hf-action ; randomized ; exercise ; training ; hf
report ; cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ; exercise rehabilitation ; patient ; chronic heart failure ; chf ; clinical ; cardiopulmonary exercise testing ; cpet ; exercise rehabilitation ; china
aa ; ischemic hf ; pathogenesis ; nyha functional class iv ; estimated glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
hf-action ; randomized ; exercise ; training ; patients ; hf ; left ventricular ejection fractions ; hrqol ; kansas city cardiomyopathy questionnaire ; kccq ; baseline
crt ; systolic dysfunction ; outcomes ; resynchronization reverses remodeling in systolic left ventricular dysfunction ; reverse ; patients ; left ventricular ; ejection fraction ; lvef
estimated glomerular filtration rate ; egfr ; type 2 diabetes ; cholesterol ; ldl-cholesterol ; clcnka ; genotype
echocardiography ; lv end-diastolic dimension ; lv end-diastolic pressure ; wall stress ; lung ; acf
diagnostic ; patients ; auc ; auc
patients ; follow-up ; patients ; spironolactone ; hospitalization ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval
rate-control ; patients ; cardiac ; driven ; cardioversions ; costs ; antiarrhythmic drugs ; cad ; patient ; confidence interval ; patient
patients ; bundle branch morphology ; diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin ii receptor blocker
eplerenone post myocardial infarction heart failure efficacy and survival study ; ephesus ; post-myocardial infarction ; patients ; heart failure ; mortality ; hospitalizations ; patients ; randomized ; aldosterone antagonist ; eplerenone
carvedilol ; metoprolol ; endpoint ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
confidence interval ; heart ; mortality ; death
dash ; clinic ; brachial systolic pressure ; central end-systolic pressure
patients ; hf ; obese ; body mass index ; idiopathic-dilated cardiomyopathy
all-cause mortality ; hospitalization ; hf ; lvef ; patients ; heart failure survey ; israel
patients ; left ventricular ejection fraction ; world health organization ; idiopathic dilated cardiomyopathy ; coronary angiography ; followed up
european society of cardiology ; hfpef ; symptoms ; heart failure ; preserved lv ejection fraction ; non-dilated left ventricle ; evidence ; diastolic dysfunction ; lv relaxation ; lv diastolic stiffness ; elevated ; lv filling pressures
β1ars ; s1pr1s ; myocyte ; camp ; report ; receptors ; g-protein-coupled receptor ; kinase-2
follow-up ; paf-cpt ; paf ; lyso-paf-at ; downregulated ; paf-ah ; lp-pla2 ; elevated
patients ; heart failure ; ejection fraction ; cardiac rehabilitation ; walking ; exercise
hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal muscle ; t-score ; fontan ; sarcopenic range muscle wasting ; t-score ; clinically ; t-score
exercise ; testosterone ; baseline ; peak oxygen uptake ; beck depression inventory ; leg ; medical outcomes study short-form ; quality of life ; exercise ; placebo
β-blocker ; uptitrations ; composite end-point ; all-cause mortality ; hf ; readmissions ; hfref ; hazard ratio ; confidence interval
patients ; heart failure ; outcomes ; exercise ; training ; hf-action ; exercise ; perceived social support score ; psss ; barriers to exercise score ; btes
univariable analysis ; st2 ; death ; hospitalization ; hazard ratio ; cardiovascular death ; hf ; hospitalization ; hazard ratio ; all-cause mortality ; hazard ratio ; hazard ratios
patients ; new york heart association class i ; fontan ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dxa ; calf ; muscle ; magnetic resonance spectroscopy ; healthy
placebo ; dopamine ; nesiritide ; bolus ; diuretic ; therapy ; renal function ; patients ; acute heart failure ; renal dysfunction
randomized ; crt ; patients ; new york heart association class iii ; heart failure ; left ventricular ejection fraction ; qrs duration ; echocardiographic ; evidence ; left ventricular dyssynchrony
patients ; left ventricular ; ejection fraction ; stable hf ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus velocities ; systole ; diastole
patients ; acute coronary syndromes ; patients ; stable ; cad ; bnp ; nt-probnp ; cad ; prognostic ; clinical ; outcome
baseline ; patients ; hf ; lyso-paf-at ; paf-cpt ; paf ; paf-ah ; lp-pla2
medical therapy ; patients ; redo sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve ; patients ; transcatheter aortic valve procedure ; surgery ; aortic valve
plasma n-terminal pro-b-type natriuretic peptide ; nt-probnp ; patients ; acute heart failure ; hf ; admission ; emergency department
cardiac troponin t ; ctnt ; n-terminal pro-b-type natriuretic peptide ; nt-probnp ; biomarkers ; hf ; hf ; atherosclerosis risk in communities ; aric
body mass index ; fat mass ; fat-free mass
interquartile range ; body mass index ; interquartile range ; copd ; chf ; crf
reverse remodeling ; ejection fraction ; mortality ; all-cause hospitalizations ; hf ; hospitalizations ; dialysis ; patients
covariates ; lv contractility ; lvef ; β coefficient ; confidence interval ; systolic blood pressure ; end-systolic volume ; β coefficient
echocardiography ; dilated lv ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mva
double-blind ; clinical ; renal optimization strategies evaluation ; rose ; hospitalized ; patients ; acute heart failure ; renal dysfunction ; estimated glomerular filtration rate ; randomized ; admission
bets ; signal transduction ; pol ii ; transcription factor ; hf ; pathogenesis ; nuclear factor of activated t cells ; nfat ; nuclear factor-κb ; nf-κb ; transcription factor ; gata4
outcomes ; mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
cardiovascular mortality ; multivariable adjustment ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
eo-cfus ; diabetes ; patients ; diabetes ; peak vo2 ; patients ; diabetes ; eo-cfus ; peak vo2
immunoblotting ; video edge detection ; epifluorescence microscopy ; myocardial tissues ; cardiomyocytes ; hf
east ; early treatment of atrial fibrillation for stroke prevention trial ; randomize ; patients ; stroke ; rhythm control therapy ; prospective ; randomized ; outcome
outcomes ; exercise capacity ; peak oxygen consumption ; vo2 ; co-primary outcome ; qol ; minnesota ; heart failure ; heart ; qol ; co-primary outcome
proteomic ; mitochondrial-targeted peptide ; ss31 ; mitochondrial function ; tac ; clinical ; mitochondrial-targeted peptide ; drugs ; heart failure
patients ; left ventricular ejection fraction ; patients ; hf ; preserved left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient ; epidemic ; medical ; financial costs
hf ; patients ; hfref ; left ventricular ; ejection fraction ; hfpef ; echo-doppler ; n-terminal pro-brain-type natriuretic peptide ; adverse events
eds ; comorbidities ; hospitalized ; adjusted odds ratio ; aor ; confidence interval ; eds ; aor
patients ; cardiac transplant ; ecct ; patients ; diabetes mellitus ; chronic kidney disease ; estimated glomerular filtration rate
habc battery ; health abc hf risk model ; change ; c-index ; net-reclassification-improvement ; hf
cfi ; rmsea ; self-care maintenance ; cfi ; rmsea ; self-care management ; cfi ; rmsea ; self-care confidence
patients ; bat ; patients ; quality-of-life ; nyha functional class ; change
patients ; preoperative ; hypoalbuminemia ; postoperative ; albumin ; hypoalbuminemia ; albumin ; lvad
rehospitalization ; confidence interval ; acute myocardial infarction ; ami ; complications ; kidney infection ; urinary tract infection ; uti ; complications
patients ; heart failure ; hf ; ischemic ; nonischemic cardiomyopathies ; pharmacological ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; right ventricular assist devices
saf ; catheterization ; central venous pressure ; svr ; cardiac index
admission ; bnp ; reduced ef ; preserved ef ; bnp ; ef
heart failure ; admission ; heart transplantation ; lv assist device ; death ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval ; ischemic ; functional class
lv ejection fraction ; shortening ; systolic elastance ; contractile efficiency ; acf ; acf ; allopurinol ; cardiomyocytes ; extracellular flux analyzer
prospectively ; patients ; hfpef ; lv hypertrophy ; lvh ; relative wall thickness ; rwt ; lvh ; rwt ; lvh ; rwt ; lvh ; rwt
lcz696 ; angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor ; prodrug ; angiotensin receptor antagonist ; valsartan ; hypertension ; heart failure with preserved ejection fraction ; outcomes ; heart failure with reduced ejection fraction
blood pressure ; mitral valve plasty ; degenerative mr ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; physio ring 30 ; edwards lifesciences ; irvine
outcomes ; incremental shuttle walk test ; peak oxygen uptake ; muscular ; echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory ; beck depression inventory ; health-related quality of life ; minnesota living with heart failure questionnaire ; medical outcomes study short-form
interaction term analysis ; lvef ; patients ; patients ; mortality ; lvef ; p value
wistar-kyoto ; zsf1 ; obese ; zsf1 ; obese ; zsf1 ; followed up ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
kaplan-meier curves ; log-rank testing ; risk stratification ; patients ; patients
multivariate cox regression analyses ; hypertension ; sinus rhythm ; hazard ratio ; confidence interval
patients ; chronic ; hf-ref ; nyha functional class ii ; egfr ; potassium ; eplerenone ; hyperkalemia
ffm ; dual energy x-ray absorptiometry ; dxa ; patients ; chronic heart failure ; chf ; non-cachectic chf ; myocardial
baseline ; drug ; spironolactone ; combined end point ; death ; hospitalization ; hf ; hazard ratio ; confidence interval ; aas ; hazard ratio ; confidence interval ; p value
prospective study ; patients ; invasively ; diagnosed ; pulmonary arterial hypertension ; inoperable ; chronic thromboembolic pulmonary hypertension ; right ventricular ; pump ; stable ; pulmonary arterial hypertension ; medication ; noninvasive ; stress echocardiography ; cardiopulmonary exercise testing
cardiovascular death ; hf ; hospitalization ; randomization ; btes ; btes ; cardiovascular death ; hf ; hospitalization ; exercise ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
patients ; hospitalized ; death ; all-cause readmission ; aor ; eds ; aor
patients ; implantable cardioverter-defibrillator ; implantation ; engage ; patients ; decisions ; implantable cardioverter-defibrillator
cardiac magnetic resonance ; t1 time ; hazard ratio ; confidence interval ; left atrial area ; hazard ratio ; confidence interval ; pulmonary vascular resistance ; hazard ratio ; confidence interval ; cardiac events
prospectively ; followed up ; hf ; patients ; systolic ; left ventricular ejection fraction ; hf ; stable ; clinical ; conditions ; new york heart association class i ; clinical ; echocardiographic ; cardiopulmonary exercise test
patients ; end stage heart failure ; abcd classification ; american college of cardiology ; acc ; american heart association ; aha ; new york heart association ; nyha ; heart disease ; symptoms ; heart failure ; physical ; medical treatment
mva ; continuity equation ; lv end-diastolic volume ; lv end-systolic volume ; mitral filling flow ; mva ; mitral filling flow ; continuous wave doppler echocardiography ; mitral valve plasty
significance ; rm ; all-cause mortality ; sts ; hh ; cri ; cri ; cri
hfpsi ; hf ; clinic ; outcomes ; hfpsi ; outcomes ; tracking ; patients ; hfpsi
aas ; spironolactone ; hyperkalemia ; potassium ; hypokalemia ; potassium
multivariate analysis ; patients ; preserved lvef ; mortality ; patients ; lvef ; hazard ratio ; lvef ; preserved lvef
patients ; hfpef ; primary outcome ; odds ratio ; nyha class iii ; 6-minute walk test ; 6-mwt ; feet ; prescribed ; medications
echo-derived pulmonary arterial systolic pressure ; pasp ; right ventricular ; rv ; tricuspid annular plane systolic excursion ; tapse ; diastole ; end-systole ; clinical ; follow-up ; heart failure ; hf ; patients ; cardiac
cad ; diabetes ; odds ratio ; electrocardiographic q waves ; left bundle branch block ; odds ratio ; nondiabetes ; dyslipidemia ; hypertension ; odds ratio
area under the receiver operating characteristic curve ; auc ; pcwp ; confidence interval ; septal ; p values
patients ; coronary artery disease ; hypertension ; trastuzumab ; administration ; chf
lvef ; clinical ; crt ; crt ; systolic volume index ; lv mass
tgf-β signaling ; tgf-β receptor type i ; cell ; yield ; epithelial ; mesenchymal ; transition ; pluripotency marker ; nanog ; cell ; cells ; in vitro
patients ; hfref ; diuretics ; co-morbidities ; 6-mwt ; feet ; nyha class iii
surgery ; hf ; postoperative ; echocardiography ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mitral valve area ; mva
patients ; systolic heart failure ; ejection fraction ; randomized ; placebo ; ivabradine ; shift ; systolic heart failure treatment with the if inhibitor ivabradine trial ; patients ; placebo ; ivabradine ; echocardiographic
hazard ratios ; multivariate regression ; tapse ; pasp ; hazard ratio ; tapse ; new york heart association functional class
renal function ; the chronic kidney disease epidemiology collaboration ; patients ; estimated glomerular filtration rate ; egfr
prospective ; randomized ; paradigm-hf ; chronic heart failure ; systolic dysfunction ; lv ef ; functional class ; nyha ; elevated ; bnp ; nt-pro bnp ; primary endpoint ; cardiovascular death ; hospitalization ; heart failure ; arni ; lcz696 ; sacubiltril ; valsartan
lv reverse remodeling ; lv end-diastolic dimension ; longitudinal ; strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial ; right ventricular fractional area ; change
hyperkalemia ; outcomes ; african americans ; aas ; new york heart association ; nyha ; hf ; left ventricular dysfunction ; randomized ; spironolactone ; titrated ; placebo ; randomized aldactone evaluation study ; rales
irs1 ; irs2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; irs1 ; irs2 ; heart-specific irs1 and irs2 gene double-knockout ; h-dko ; liver-specific irs1 and irs2 double-knockout ; l-dko
b-type natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; diagnostic ; stable ; coronary artery disease ; b-type natriuretic peptide ; bnp ; nt-probnp ; ventricular cardiomyocytes ; ventricular ; wall stress ; myocardial ischemia
prescription ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; interquartile range ; β-blockers ; interquartile range ; interquartile range
therapy ; ivabradine ; change ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity ; correlates ; exercise capacity ; therapy ; ivabradine ; correlated ; peak oxygen uptake
evidence ; transfusion ; mortality ; relative risk ; mortality ; patients ; acute coronary syndrome
death ; readmission ; patients ; physician ; hazard ratio ; confidence interval ; physician ; follow-up ; patients ; follow-up
hek ; human embryonic kidney ; cells ; β1ar ; s1pr1 ; β1ar ; downregulation ; sphingosine-1-phosphate ; s1pr1 agonist ; s1pr1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
baseline ; training ; 6-minute walked distance ; quality of life ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; symptoms ; beck depression inventory ; zung self-rated depression scores ; b-type natriuretic peptide ; endothelial function ; flow-mediated dilatation ; left ventricular diastolic function
odds ratios ; confidence intervals ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; patients ; estimated glomerular filtration rate ; nonsignificant ; acute kidney injury
diastolic function ; ea ; ventricular-arterial coupling ; ees ; ea
hazard ratios ; disease risk score ; drs ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
patients ; revascularization ; coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline ; electrocardiogram
biomedical ; biomedical ; relative risk ; confidence interval ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
prospective ; randomized ; crossover study ; outcome ; stable heart failure ; patients ; left ventricular ejection fraction ; homozygous ; haplotype ; β2-receptor ; randomized ; carvedilol ; metoprolol
patients ; death ; hospitalization ; aor ; aor ; aor ; aor
health buddy program ; all-cause mortality ; hazard ratio ; confidence interval ; inpatient ; admissions ; baseline
multivariable-adjusted hazard ratios ; dash
ctnt ; nt-probnp ; report ; aric ; hf ; systolic blood pressure ; antihypertensive medication ; diabetes ; body mass index ; coronary heart disease ; heart rate ; hf ; area under the receiver operating characteristic curve ; auc ; integrated discrimination improvement ; net reclassification improvement ; nri
eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; patients ; heart failure and reduced ejection fraction ; hf-ref ; new york heart association ; nyha ; functional class ; estimated glomerular filtration rate ; egfr ; serum potassium
nesiritide ; nesiritide ; placebo ; change ; cystatin c ; nesiritide ; placebo
walking ; functional capacity ; 6mwt ; physical ; activity ; symptoms ; hospital anxiety and depression scale
patients ; hyperkalemia ; patients ; diabetes ; egfr ; systolic blood pressure ; potassium ; hyperkalemia ; leading ; hospitalization ; hospitalization ; primary outcome ; hospitalization ; hf ; cardiovascular mortality
paf ; biosynthetic enzymes ; lyso-paf acetyltransferase ; lyso-paf-at ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; paf-cpt ; catabolic isoenzymes ; paf-acetylhydrolase ; paf-ah ; lipoprotein-associated phospholipase a2 ; lp-pla2 ; leukocytes
ivabradine ; baseline ; follow-up ; exercise capacity ; mets ; mets ; peak oxygen uptake ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
multivariate analysis ; chf ; odds ratio ; chest ; hypertension ; genes ; rac2 ; doxorubicin efflux transporter ; abcc2
baseline ; follow-up ; nyha classification ; patients ; patient ; change ; patient ; quality of life ; duke activity status index ; kansas city cardiomyopathy questionnaire ; 6 min walk test
placebo ; dopamine ; dopamine ; placebo ; change ; cystatin c ; dopamine ; placebo
hazard ratio ; confidence interval ; baseline ; glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; new york heart association class ; atrial fibrillation ; congestive hf ; mortality
multivariable analysis ; end point ; peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
6-minute walked distance ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; beck depression inventory ; flow-mediated dilatation ; fes ; placebo ; b-type natriuretic peptide ; mitral
